ATM Expression in peripheral blood mononuclear cells as a biomarker of insulin resistance by Williams, Lois Esther
ATM EXPRESSSION IN PERIPHERAL BLOOD MONONUCLEAR CELLS AS A 
BIOMARKER OF INSULIN RESISTANCE 
By 
Lois Esther Williams 
“Thesis presented in fulfilment of the requirements of the degree of Master of Science in the 
Faculty of Medicine and Health Sciences at Stellenbosch University” 
Supervisor: Prof Barbara Huisamen 
April 2019
II 
DECLARATION 
By submitting this thesis electronically, I declare that the entirety of the work contained therein is 
my own, original work, that I am the sole author thereof (save to the extent explicitly otherwise 
stated), that reproduction and publication thereof by Stellenbosch University will not infringe any 
third party rights and that I have not previously in its entirety or in part submitted it for obtaining 
any qualification. 
Date:  April 2019
Copyright© 2019 Stellenbosch University 
All rights reserved 
Stellenbosch University  https://scholar.sun.ac.za
III 
ABSTRACT 
Introduction: The Ataxia Telangiectasia Mutated (ATM) gene codes for the 350 kDa ATM protein 
kinase. ATM gene mutations cause inactivity/deficiency of the ATM protein, resulting in the 
autosomal recessive disease Ataxia Telangiectasia (AT). AT patients are predisposed to developing 
insulin resistance or further progress to type 2 diabetes and are at high risk of developing 
ischaemic heart disease. Due to the prevalence of insulin resistance in AT patients, we investigated 
the relationship between ATM protein levels and the degree of insulin resistance and proposed it 
as a possible early diagnostic technique for insulin resistance. 
Aim: To determine whether peripheral blood mononuclear cells (PBMCs) can be used to 
determine ATM levels in insulin resistant subjects and subsequently used as a biomarker of insulin 
resistance. 
Objectives: (i) To standardise a protocol for the isolation of PBMCs from rat blood. (ii) To isolate 
rat PBMCs and determine the ATM levels using Western blotting. (iii) To determine differences 
between ATM levels in obese rats and compare them to controls. (iv) To analyse PBMCs from a 
female Black Xhosa population with different degrees of insulin resistance and to determine a 
relationship with ATM levels. 
Methods: Male Wistar rats were fed an obesogenic diet (od) for 16 weeks to induce obesity and 
insulin resistance and compared to age-matched and young controls fed standard rat chow. Body 
weight and intraperitoneal (IP) fat mass were determined and oral glucose tolerance test (OGTT) 
was performed. PBMCs were isolated according to the standardised protocol and Western blotted 
for ATM and P22phox. The Western blotting protocol was repeated with samples collected from 
patients.  
Results from the animal model: 1. Effects of obesity/insulin resistance vs. age-matched controls: 
(i) larger IP fat mass; (ii) increased area under the curve of OGTT’s; (iii) elevated basal glucose 
levels. (iv) The phospho-(P)/total-(T) ATM ratio was decreased.   
2. Effects of age: (i) As expected, older animals weighed more while T-ATM was decreased, P-ATM
increased and the P-/T-ATM ratio increased with age. 
In PBMC’s from patients, the following were observed: (i) Body mass index (BMI) was significantly 
higher in obese and pre-diabetic vs. control patients. (ii) The waist-to-hip ratio (WHR) of obese and 
pre-diabetic women was higher vs. controls. (iii) Trunk-to-limb fat mass (TF/LF) was increased in 
obese and pre-diabetics vs. controls but (iv) no differences in the lipid profiles were observed 
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except for increased triglyceride levels between young pre-diabetic patients vs. their controls. (v) 
Fasting blood glucose of obese and pre-diabetic patients was significantly increased vs. controls. 
(vi) Significantly higher P-ATM levels were seen for obese and pre-diabetic vs. control patients. T-
ATM levels increased with the state of insulin resistance.   
Effects of age: (i) BMI was significantly higher between young (Y) and middle aged (MA) control, 
obese and pre-diabetic groups vs. their respective controls while (ii) WHR  of Y obese and Y pre-
diabetic vs. Y controls also increased significantly. (iii) The TF/LF ratio was increased between Y 
and MA control and Y obese, Y pre-diabetic, MA obese and MA pre-diabetic women vs. their 
respective controls. Furthermore (iv) the blood glucose levels of Y pre-diabetics were increased vs. 
Y control. (v) The P-ATM levels was increased in Y pre-diabetic vs. Y control and therefore did not 
increase with age but the T-ATM levels significantly increased with age. 
Conclusion: ATM levels can be measured in PBMCs and are affected by the insulin resistant state 
and age. Unfortunately, due to the variation in ATM levels under different degrees of insulin 
resistance, it would be difficult to use ATM as a biomarker of insulin resistance.  
Stellenbosch University  https://scholar.sun.ac.za
V 
OPSOMMING 
Inleiding: Die Ataxia Telangiectasia gemuteerde (ATM) geen kodeer vir die 350 kDa ATM proteïen 
kinase.  Mutasies in die ATM geen lei tot uitdrukking van geen of onaktiewe proteïen wat die 
outosomaal resessiewe siekte, Ataxia Telangiectasia (AT), veroorsaak.  AT pasiënte is voorbeskik 
om insulienweerstandigheid of tipe 2 diabetes te ontwikkel en het ‘n hoë risiko vir iskemiese 
hartsiektes.  Na aanleiding van die prevalensie van insulienweerstandigheid in AT pasiënte, het ons 
die verhouding tussen ATM proteïenvlakke en die graad van insulienweerstandigheid bestudeer en 
dit voorgestel as ‘n moontlike vroeë diagnostiese tegniek vir insulienweerstandigheid.  
Doel: Om te bepaal of perifere bloed mononukluêre selle (PBMCs) gebruik kan word om ATM 
vlakke in insulienweerstandige subjekte te meet en te bepaal of dit as biomerker vir 
insulienweerstandigheid gebruik kan word. 
Objektiewes: Om (i) ‘n protokol vir die isolasie van PBMCs uit rot bloed te standardiseer. (ii) Rot 
PBMCs te isoleer en die ATM vlakke met behulp van Westerse kladtegniede te bepaal. (iii) Verskille 
tussen ATM vlakke in vetsugtige rotte te vergelyk met kontrole rotte. (iv) PBMCs verkry van Swart 
vroulike Xhosa pasiënte met verskillende grade van insulienweerstandigheid te analiseer en die 
verhouding met ATM uitdrukking te bepaal. 
Metodes: Manlike Wistarrotte is vir 16 weke met ‘n obesogene dieet gevoer en vergelyk met 
ouderdomsgepaarde en jong kontrole diere op standaard rotkos. Liggaamsgewig en 
intraperitoneale (IP) vetgewig is bepaal en ‘n orale glukosetoleransie toets (OGTT) uitgevoer. 
PBMCs is geïsoleer deur die gestandardiseerde metode en ATM en P22phox deur Westerse 
kladtegnieke bepaal. Die Westerse kladtegniek is op die pasiënte monsters herhaal. 
Resultate verkry van die diermodel: 1. Effekte van obesiteit/insulienweerstandigheid vs. 
ouderdomsgepaarde kontroles: (i) groter IP vetmassa; (ii) verhoogde area onder die kurwe van die 
OGTT’s (iii) verhoogde basale bloedglukosevlakke is gemeet.  (iv) Die fosfo-(P)/totale (T) ATM 
verhouding was verlaag. 
2. Effekte van ouderdom: (i) soos verwag, het die ouer diere meer geweeg terwyl T-ATM vlakke
verlaag het, P-ATM verhoog en die P/T verhouding beduidend verhoog het met ouderdom. 
In PBMC’s van pasiënte is die volgende waargeneem: (i) die liggaamsmassaindeks (LMI) was 
beduidend hoër in die vetsugtige en pre-diabetiese pasiënte vs. kontroles. (ii) die middel-tot-heup 
(MTH) verhouding van vetsugtige en pre-diabetiese vroue was hoër as die kontroles. (iii) Die romp-
tot-ledemaat (RV/LV) vetmassa was verhoog in die vetsugtige en pre-diabetiese vroue vs. 
Stellenbosch University  https://scholar.sun.ac.za
VI 
 
kontroles maar (iv) geen verskille in die lipiedprofiele is waargeneem nie, buiten verhoogde 
trigliseriedvlakke tussen jong pre-diabetiese pasiënte vs. hulle kontroles. (v) Vastende 
bloedglukose van vetsugtige en pre-diabetiese pasiënte was beduidend hoër as kontroles. (vi) 
Beduidend hoër P-ATM vlakke is waargeneem in die vetsugtige en pre-diabetiese vs. kontrole 
pasiënte. T-ATM vlakke het verhoog met die staat van insulienweerstandigheid. 
Effekte van ouderdom: (i) LMI was beduidend hoër in die jong (J) en middeljarige (MJ) kontrole, 
vetsugtige en pre-diabetiese groepe vs. hulle onderskeie kontroles terwyl (ii) die MTH van die J 
vetsugtige en pre-diabetiese vs. J kontroles ook beduidend hoër was. (iii) Die RV/LV verhouding 
het toegeneem tussen J en MJ kontrole en J vetsugtig, J pre-diabeties, MJ vetsutgig en MJ pre-
diabetiese vroue vs. hulle onderskeie kontroles. Verder (iv) was die bloedglukosevlakke van die J 
pre-diabetiese pasiënte verhoog teenoor J kontroles. (v) Die P-ATM vlakke was verhoog in die J 
pre-diabetiese vs. J kontroles en het dus nie met ouderdom verhoog nie maar die totale vlakke van 
ATM het beduidend toegeneem met ouderdom.  
Gevolgtrekking: ATM vlakke kan in PBMCs gemeet word en die vlakke word beïnvloed deur die 
insulienweerstandige staat sowel as ouderdom. Ongelukkig, as gevolg van variasies in ATM vlakke 
in die verskillende grade van insulienweerstandigheid, sal dit problematies wees om ATM as ‘n 
biomarker van insulienweerstandigheid te gebruik.     
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CHAPTER 1: LITERATURE REVIEW 
1. Ataxia Telangiectasia 
Ataxia Telangiectasia (AT) also known as Louis-Bar syndrome is an autosomal recessive disease 
caused by mutations in the AT Mutated (ATM) gene and the deficiency of the ATM protein kinase 
(Foroughizadeh et al. 2012). The mutations in the ATM gene are hereditary and cause the 
expression of inactive or no ATM protein (Lavin and Shiloh, 1997; Yang et al., 2011).  
1.1 AT symptoms and characteristics 
AT patients characteristically present with insulin resistance, an increased risk of developing type II 
diabetes mellitus (T2D) (Ristow, 2004; Lavin et al., 2007), cerebellar degeneration, 
immunodeficiency and an increased predisposition for developing cancer (Llorca et al., 2003), 
premature ageing (Shiloh and Lederman, 2017) and ischaemic heart disease (van Os et al., 2016). 
Ataxia refers to the loss of coordinated body movements which occurs in AT patients due to 
cerebellar ataxia and subsequent neurodegeneration (Khalil, Tummala and Zhelev, 2012). Ataxic 
gait and truncal movements are seen when AT children start walking and the cerebellar 
degeneration processes affecting speech and movement causing immobilisation by the end of 10 
years of age (Lavin and Shiloh, 1997). Telangiectasia is when dilated capillaries and veins become 
visible under the skin and on the nose, ears, conjunctiva of the eye and behind the knees (Khalil, 
Tummala and Zhelev, 2012) usually between the ages of 2 and 8 years (McFarlin, Strober and 
Waldmann, 1972; Boder E., 1985).  
2. Overview of ATM gene and protein 
2.1 ATM gene  
ATM is a human tumour suppressor gene which codes for the 350 kDa protein, Ataxia 
Telangiectasia Mutated protein kinase (ATM) (Llorca et al., 2003). The ATM protein kinase was 
discovered when the deficiency thereof caused the characteristics found in the AT disease. The 
ATM gene was mapped and localised to chromosome 11q22-23 (Gatti et al., 1988). Mutations in a 
specific gene were found to cause the phenotypes seen in AT patients and was named the ATM 
gene (Savitsky et al., 1995).  
2.2 ATM protein kinase 
ATM forms part of the phosphatidylinositol 3 (PI3) kinase protein family (Zhou et al., 2011) and is a 
complex protein taking part in a number of physiological processes such as cell cycle regulation 
(Llorca et al., 2003) metabolic regulation, oxidative stress, cell proliferation, transcriptional 
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modulation, protein degradation and DNA double-strand break repair (DSBR)  (Khalil, Tummala 
and Zhelev, 2012). ATM is the main regulator in the response to Deoxyribonucleic acid (DNA) 
damage as well as regulating cell-cycle checkpoint activation, DNA repair and changes in 
metabolism due to DNA double-strand breaks (DSBs) (Paull, 2015). ATM exists as an inactive dimer 
but splits into its monomers when activated by DNA DSBs (Bakkenist and Kastan, 2003).  
ATM is expressed as a serine/threonine (Ser/Thr) protein kinase in the nucleus (Chen and Lee, 
1996; Scott et al., 1998). During attacks to the genome, existing ATM is activated by 
phosphorylation of serine residues (Bakkenist and Kastan, 2003; Kozlov et al., 2006) causing the 
protein to dissociate into its monomers for DNA repair (Bakkenist and Kastan, 2003). ATM is 
considered a housekeeping gene and is predominantly located in the nucleus (Gately et al., 1998) 
where its basal levels exist as phosphorylated at Ser-1981 (Khalil, Tummala and Zhelev, 2012). 
2.3 Localisation and functions of ATM 
According to Khalil et al. (2012) a number of studies have investigated the localisation of ATM 
where it was found in compartments such as peroxisomes, endosomes, Golgi apparatus, plasma 
membrane, nucleus and the cytoplasm and cytoplasm vesicles. According to Yang et al. (2011), 
ATM’s activation by DNA DSBs and subsequent cell cycle arrest is only due to the functioning of 
the ATM located in the nucleus and cannot explain the other characteristic disorders seen in AT 
patients. Most of the identified functions of ATM were deduced from its amino acid sequence, 
however more than 90% of its sequence’s function has not yet been identified (Yang et al., 2011). 
Nuclear ATM 
A study was done to determine the localisation of ATM where cells were sub-fractionated into 
cytoplasmic, microsomal and nucleic fractions and it was found to localise in the nucleus and 
microsomal fractions (Watters et al., 1997). ATM located in the nucleus specifically responds to 
DSBs of DNA (Abraham, 2001). It furthermore functions as a cell-cycle checkpoints regulating 
protein when activated by the DNA DSBs where it phosphorylates downstream effectors (Llorca et 
al., 2003). The phosphorylated downstream effectors and proteins stop the cell cycle, recruits DNA 
repair proteins (Khalil, Tummala and Zhelev, 2012) or, during severe DNA damage, apoptosis is 
initiated (Lee and McKinnon, 2000). Yang et al. (2011) suggested that, as ATM functions as a 
regulator of cell-cycle checkpoints and repairs damaged DNA, this would explain why AT patients 
are prone to developing cancer.  
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Cytoplasmic ATM 
As previously stated by Yang et al. (2011) it was suggested that other characteristics seen in AT 
patients could be attributed to ATM localised elsewhere in the cell. In studies done in neuronal 
cells, ATM was found to be mainly localised in the cytoplasm (Oka and Takashima, 1998; Barlow et 
al., 2000; Boehrs et al., 2007). It was also reported that ATM is present in the cytoplasm of 
proliferating cells where it interacts with beta (β)-adaptin (a cytoplasmic vesicle trafficking protein) 
(Lim et al., 1998). Furthermore, links between cytoplasmic ATM and a role in insulin signalling was 
found (Yang and Kastan, 2000; Viniegra et al., 2005; Halaby et al., 2008).  
Mitochondrial ATM 
According to Valentin-Vega et al. (2012), a fraction of ATM is localised in the mitochondria and is 
activated during mitochondrial dysfunction. A study investigating mitochondrial dysfunction in AT, 
analysed mice thymocytes and found an increase in the number of altered mitochondria under AT 
conditions (Valentin-Vega et al., 2012). Furthermore, thymic cells from ATM null mice were found 
to contain higher mitochondrial mass and increases in mitochondrial reactive oxygen species 
(mROS). Valentin-Vega et al. (2012) deduced from their data that the increase in mitochondrial 
mass is possibly due to a decrease in mitophagy. Overall it was found that ATM deficiency caused 
mitochondria to be abnormal and dysfunctional; increased production of mROS and decreased 
mitophagy. Subsequently it was hypothesised that ATM may play a role in mitochondrial function 
and reactive oxygen species (ROS) production (Valentin-Vega et al., 2012). 
3. ATM in insulin signalling 
The relationship between ATM and insulin signalling has not been fully established and is still 
largely been researched. Studies investigating the function of ATM in the cytoplasm have 
discovered its role as an insulin-responsive protein and hypothesised that a defect in this response 
could be responsible for the development of insulin resistance and T2D in AT patients (Yang and 
Kastan, 2000).  
Yang and Kastan (2000) investigated the phosphorylation of eukaryotic translation initiation factor 
4E (eIF-4E) - binding protein 1 (4E-BP1) causing the release of eIF-4E through insulin treatment for 
protein synthesis. The study reported that (i) ATM phosphorylates 4E-BP1 at Ser-111 in vitro and 
insulin treatment caused the phosphorylation of 4E-PB1 at Ser-111 in vivo ATM-dependently (Yang 
and Kastan, 2000) (Figure 1.1) . These findings were in agreement with a previous study, where 
insulin treatment was found to cause kinase activity that phosphorylated Ser-111 of 4E-BP1 
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(Heesom et al., 1998). This kinase activity resembled that of ATM (Yang and Kastan, 2000) and was 
inhibited by wortmannin (PI3 kinase inhibitor) but not by rapamycin (an inhibitor of the 
mammalian target of rapamycin (mTOR)) (reviewed in (Yang and Kastan, 2000)). Insulin treatment 
was found to cause a two-fold increase in ATM kinase activity in HEK (human embryonic kidney) 
293 cells irrespective of the substrate and a three-fold increase in 3T3 L1 mice cells, differentiated 
into adipocytes. It was suggested that (ii) 4E-BP1 phosphorylation occurs on Thr-36 and Thr-45 via 
the PI3K/protein kinase B (PKB)/mTOR pathway and on Ser-111 ATM-dependently (Yang and 
Kastan, 2000) (Figure 1.1).  
For the relevance of this review, the PI3K/PKB/mTOR pathway will not be discussed in detail. 
 
Figure 1.1: Pathways with ATM as a role playing protein. Dotted arrows indicate multiple reactions 
in between. Dotted pathways with question marks have yet to be fully investigated. Ataxia 
Telangiectasia Mutated (ATM), Protein kinase B (PKB), AMP-activated protein kinase, 
Phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), Eukaryotic translation 
initiation factor 4E – binding protein 1 (4E-BP1), Eukaryotic translation initiation factor 4E (eIF-4E), 
NADPH oxidase 2 (NOX2), Reactive oxygen species (ROS), glucose transporter 4 (GLUT4), Serine 
(Ser), phosphorylated (P). 
A study by Viniegra et al. (2005) investigating the relationship between PKB and ATM, found that 
(iii) ATM induced phosphorylation of PKB Ser-473 during insulin treatment; however they were not 
able to determine whether ATM phosphorylated PKB directly (Figure 1.1). It was concluded that, 
although ATM does not seem to phosphorylate PKB directly, it acts as an upstream regulator of 
PKB Ser-473 phosphorylation (Viniegra et al., 2005). Following insulin release, PKB is activated in 
the PI3K pathway and is responsible for protein translation (Lawrence and Abraham, 1997; 
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Sonenberg, Hershey and Mathews, 2000) as well as initiating glucose transporter type 4 (GLUT4)  
translocation to the membrane for glucose uptake (Pessin and Saltiel, 2000; Bryant, Govers and 
James, 2002).  
A study by Halaby and colleagues (2008) investigated ATM expression and PKB phosphorylation in 
muscle tissue of rats fed with an insulin resistance-inducing high-fat diet. The results showed a 
decrease in ATM expression in the insulin resistant animals when compared to the controls. 
Halaby et al. (2008) suggested that low PKB activity is the main factor responsible for the 
development of ineffective glucose uptake and insulin resistance in the rats fed a high-fat diet, 
however the stage of the insulin signalling pathway at which deficiency starts, could not be 
determined. It was hypothesised that, as common characteristics of AT patients are insulin 
resistance that could develop into T2D and glucose intolerance, it could be plausible that 
decreased ATM expression levels may contribute to the development of insulin resistance in the 
high-fat diet rat model by causing the decrease in PKB activity (Halaby et al., 2008). It was found 
that there was no decrease in the expression or activation of the insulin receptor substrate 1 (IRS-
1) in AT cells when compared to normal cells and it was suggested that AT cells have a possible 
defect in intracellular insulin signalling (Halaby et al., 2008). Furthermore, it was suggested that, as 
PKB is responsible for GLUT4 translocation for glucose uptake, the deficiency of ATM may down 
regulate the activation of PKB and subsequently the translocation of GLUT4, ultimately leading to 
glucose intolerance and insulin resistance symptoms seen in AT patients and in high-fat diet rat 
models (Halaby et al., 2008). 
4. ATM and adipocyte function 
Takagi and colleagues (2015) hypothesised that adipocyte dysfunction is responsible for glucose 
intolerance and insulin resistance in AT individuals. In a study using knockout ATM mice, the mice 
were found to be insulin resistant and to have less subcutaneous adipose tissue when compared 
to wild-type mice (Takagi et al., 2015). With further in vitro investigation in mice embryonic 
fibroblasts (MEF), it was found that adipocyte differentiation was impaired in ATM-/- cells due to a 
deficiency of important transcription factors for the induction of adipocyte differentiation (Takagi 
et al., 2015). Takagi and colleagues (2015) further reported an ATM function not previously 
characterised, where ATM regulates important adipocyte transcription factors.  
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5. ATM and insulin resistance 
Insulin resistance is commonly observed amongst AT patients. According to Yang et al. (2011), AT 
patients usually die within the first 30 years of age while T2D is usually diagnosed later in life, 
normally from 40 years of age, and it has been speculated that the percentage of AT patients 
found to have T2D may have been misrepresented (Robinson and Kessling, 1992). An oral glucose 
tolerance test (OGTT) study was performed by Yang et al. (2011), where AT individuals were found 
to show symptoms of glucose intolerance, hyperinsulinaemia and hyperglycaemia. An article in 
1970 already stated that 10 out of 17 AT patients developed T2D (Schalch, McFarlin and Barlow, 
1970). T2D develops when the β-cells of the pancreas, which secrete insulin, are unable to 
compensate for the increased glucose plasma levels (Wilcox, 2005). Further studies are needed for 
the investigation of other functions of ATM as a large number of ATM’s signalling pathways, 
especially those pathways involved in insulin signalling and glucose metabolism, are not fully 
understood. 
The first genome-wide association study (GWAS) on glycaemic response to metformin treatment 
in type 2 diabetics, identified a singular nucleotide polymorphism (SNP) at the locus containing the 
ATM gene (Zhou et al., 2011). With further investigation, the inhibition of the ATM protein was 
found to down-regulate the phosphorylation and activation of the 5' adenosine monophosphate 
(AMP)-activated protein kinase (AMPK) in response to metformin, which is the first line drug for 
T2D. Zhou and colleagues (2011) concluded that variation in the ATM gene causes a variation in 
the glycaemic response to metformin treatment.  
6. P22phox  
P22phox is a 22 kDa transmembrane protein that forms part of the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases referred to as NOXs and together generate superoxide 
(Stasia, 2016). P22phox can form a complex with NOX1, NOX2, NOX3 and NOX4 and these 
complexes were found to be important sources of ROS and are associated with a number of 
diseases such as cardiovascular disease and cerebrovascular disease (Stasia, 2016). P22phox forms a 
complex with NOX2 and forms cytochrome b558 and is mainly expressed in phagocytes where its 
function is to eliminate microorganisms during fungal and bacterial infections (Stasia, 2016). The 
importance of NOXs in eliminating ingested pathogens, via phagocytosis, was proven by chronic 
granulomatous disease (CGD) (Stasia, 2016), which is caused by a defect of the oxidase complex of 
phagocytes where patients characteristically suffer from frequent, life threatening infections (van 
den Berg et al., 2009). The absence of P22phox in X-linked CGD further motivated NOXs importance 
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(reviewed in (Stasia, 2016). Due to the discovery of NOXs as an important source of ROS, its role in 
cardiovascular diseases, namely hypertension, diabetes, kidney disease, heart failure, 
atherosclerosis and cerebrovascular disease is now broadly accepted (reviewed in (Stasia, 2016). 
While inactive, the NOX complexes are dormant and are activated when superoxide needs to be 
synthesised for phagocytosis (Stasia, 2016). Activation occurs by the assembly of all the subunits 
with cytochrome b558 which are all initiated by phosphorylation (reviewed in (Stasia, 2016)). The 
main function of P22phox is to assist with the maturation and stabilisation of the heterodimer that 
P22phox forms with the NOX enzymes (Stasia, 2016). Once assembled, electron transfer is initiated 
from NADPH to oxygen which results in oxidising species production used in phagocytosis of 
pathogens.  
A study by Delbosc et al. (2005) investigated the importance of ROS production in the 
development of cardiovascular complications that are associated with insulin resistance, using 
fructose-fed rats. The insulin resistant fructose-fed rats showed significant superoxide anion 
production which they hypothesised to be due to NOX. With further investigation, immunoblotting 
of P22phox in left ventricular tissue, showed an overexpression in insulin resistant rats (Delbosc et 
al., 2005). It was concluded that raised cardiac ROS production is linked to overexpression of 
P22phox and that this was dependent on NOX which is proven through elevated P22phox levels in 
high fructose - fed rats (Delbosc et al., 2005). 
A recent study found that (iv) once NOXs, specifically NOX2 is activated, ROS production takes 
place and superoxide is produced leading to oxidative stress, which activates ATM via 
phosphorylation. Phosphorylated ATM subsequently phosphorylates Ser-486 in NOX2 causing a 
conformational change and a decrease in ROS production (Beaumel et al., 2017) (Figure 1.1). 
7. Insulin resistance 
Insulin resistance develops when the cells have a decreased sensitivity to the secretion of normal 
or high levels of insulin in the blood causing a decrease in the overall physiological responses 
(Wilcox, 2005). Insulin resistance is found in association with a number of other diseases, known 
as clinical syndromes, such as T2D, cardiovascular disease, hypertension, certain cancers and the 
metabolic syndrome (Reaven, 2004). 
Pre-diabetic state: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) are 
considered pre-diabetic states (Bacha et al., 2010). Pre-diabetes characteristically presents with 
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elevated fasting blood glucose or abnormal glucose tolerance or both and is associated with an 
increased predisposition for developing T2D in adults (American Diabetes Association, 2004b). 
T2D: Diabetes mellitus is the insufficient metabolism of glucose subsequently initiating impaired 
glucose homeostasis of the blood (Ristow, 2004). T2D, specifically, is defined as a non-insulin-
dependent diabetes (type II) and is the most common form of diabetes mellitus which commonly 
manifests during middle age and older ages or in the presence of factors such as a sedentary 
lifestyle, obesity and the metabolic syndrome (Ristow, 2004). 
7.1 Insulin resistance and diseases 
Insulin resistance is also highly prevalent in diseases such as obesity (Lee and Lee, 2014; Oh et al., 
2017), non-alcoholic fatty liver disease (NAFLD) (Paniagua et al., 2014), which is considered the 
most common liver disorder in the world (Pala et al., 2014) as well as polycystic ovary syndrome 
(PCOS) (Dunaif et al., 1989), which is the most prevalent endocrinopathy amongst women of 
reproductive age (Pala et al., 2014). 
7.1.1 Obesity 
Obesity is a state of excessive and/ or abnormal adiposity (Wang et al., 2017) and is associated 
with other metabolic disorders such as T2D; cardiovascular disease and cancer (Hajer, van Haeften 
and Visseren, 2008). Risk factors such as adipose tissue dysfunction, mitochondrial dysfunction, 
gut microbiota dysbiosis and myofibre types have also been found to have an association with 
insulin resistance and obesity (Wang et al., 2017). During obesity, adipose tissue has stored 
triglycerides to its fullest capacity and cannot store more lipids, causing lipolysis and an increase in 
free fatty acids (FFAs) in adipose tissue (Wang et al., 2017). Obese patients are in a constant state 
of low-grade inflammation and more prone to contracting infections (Dicker et al., 2013). Body 
Mass Index (BMI) is an index of weight in kilograms (kg) over height in metres squared (m2) and is 
used for diagnosing adult obesity (Jung et al., 2016). Individuals with a BMI exceeding 30 kg/m2 are 
considered obese. The South Africa Demographic and Health Survey (SADHS) Key Indicator Report 
stated in 2016 and 2017, that 68% of women and 31% of men are overweight (BMI ≥25kg/m2) or 
obese with 1 in 5 having a BMI ≥ 35 kg/m2 classifying them as severely obese (National 
Department of Health (NDoH) et al., 2017).  Obese individuals characteristically present with waist 
circumferences exceeding 102 cm in men and 88 cm in women are considered abdominally obese 
(Hough, 2004).  
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Childhood overweight and obesity are increasing worldwide and is speculated to increase to 9% by 
2020 (de Onis, Blössner and Borghi, 2010). Excessive weight amongst the young population may 
develop into obesity-related conditions at an earlier age (Moreno et al., 2008; de Onis, Blössner 
and Borghi, 2010), namely T2D, cardiovascular disease (Baker, Olsen and Sørensen, 2008) and 
hypertension to name a few (Wabitsch, 2000; Reinehr and Wabitsch, 2011). With this in mind, 
obesity is considered a main health problem with a big effect on children, subsequently leading to 
disease in adulthood (Owen et al., 2005).  
a) Leptin and obesity 
Leptin is a circulating peptide hormone produced by adipose cells and controls body weight by 
regulating food intake and metabolism (Friedman and Halaas, 1998). Leptin resistance is 
associated with increased plasma leptin levels in obesity and is more common than leptin 
deficiency, that develops into extreme obesity (reviewed in (Bacha et al., 2010)). A number of 
studies have reported a directly proportional relationship between leptin and adipose tissue mass 
(Maffei et al., 1995; Considine et al., 1996; Zimmet et al., 1996; Mahabir et al., 2007). A Chinese 
population-based study found an independent association between leptin and all measures of 
adiposity (Zuo et al., 2013). The results showed that insulin resistant overweight or obese 
participants had significantly higher leptin concentration levels, which was almost double, when 
compared to non-insulin resistant overweight or obese participants with the same level of 
adiposity in both sexes. Zuo et al. (2013) concluded that there is an association between leptin 
levels and insulin resistance independent of the level of obesity and hypothesised that the 
relationship seen between high levels of serum leptin in insulin resistance may explain the 
variation in metabolic risk amongst individuals with the same level of obesity. Zimmet et al. (1996) 
suggested that the variation in leptin concentration was possibly also influenced by other factors 
such as physical activity, nutrition, fat distribution, genotype, insulin or other hormones and not 
only the degree of obesity (Zimmet et al., 1996). In a recent study the possibility of triglycerides 
causing leptin and insulin resistance in brain receptors were investigated where it was 
hypothesised to cause central insulin and leptin receptor resistance (Banks et al., 2018). Leptin is 
able to cross the blood-brain barrier (BBB) and binds to its receptors in the brain where it 
stimulates weight loss, the production of heat and aids the central nervous system (CNS) for 
cognitive brain function (reviewed in (Banks et al., 2018)). However, resistance of these receptors 
have been linked to increased eating, obesity and impaired cognition (Banks et al., 2018). A 
previous study found triglycerides cause peripheral leptin resistance (Banks et al., 2004). Banks 
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and colleagues (2018) found that triglycerides were able to cross the BBB and inhibit insulin and 
leptin from activating there canonical signalling pathways, subsequently affecting eating and 
cognitive brain function. 
b) Dysfunctional adipose tissue 
Adipose tissue becomes dysfunctional when it is unable to store all the excess FFAs, resulting in a 
decrease in production of adiponectin and an increased production of inflammatory cytokines 
(Coppack et al., 1992; Skurk et al., 2007). Adiponectin is an adipokine produced by adipose tissue 
and is responsible for the regulation of carbohydrate and lipid metabolism as well as regulating 
insulin sensitivity (Inoue and Tsugane, 2012). When adipose tissue is unable to store more lipids; 
lipolysis increases FFA levels in the adipose tissue (Wang et al., 2017).  FFAs are able to bind to 
macrophage toll-like receptor (TLR) 4 initiating inflammation (Shi et al., 2006) as well as activation 
of macrophages (Wang et al., 2017) present in adipose tissue. The activation of macrophages 
activates the nuclear factor-kappa B (NF-κB) pathway and subsequent synthesis and release of 
pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) (Suganami, Nishida and 
Ogawa, 2005; Suganami et al., 2007). TNF-α activates adipocytes promoting lipolysis and the gene 
expression of pro-inflammatory cytokines such as interleukin-6 (IL-6), macrophage 
chemoattractant protein-1 (MCP-1) and intracellular adhesion molecule-1 (ICAM-1) of which the 
latter two further promote the translocation of macrophages into the adipose tissue (Ruan et al., 
2002; Kanda et al., 2006; Permana, Menge and Reaven, 2006; Amano et al., 2014). In an obese 
state FFAs are constantly available allowing for the constant activation of macrophages and TLR-4 
ultimately leading to an inflammatory state (Wang et al., 2017). The inflammatory state promotes 
an imbalance in adiponectin secretion and proinflammatory markers secretion, subsequently 
leading to increased glucose production by the liver and a decrease in glucose uptake into adipose 
tissue and muscles via GLUT4 as well as the attenuation of the insulin signalling cascade (Yao et al., 
2016). The decrease in the downstream effects of insulin signalling promotes lipolysis of adipose 
tissue leading to deposition of lipids in non-adipose tissue, such as the liver and skeletal muscle, 
contributing to systemic insulin resistance (Rutkowski, Stern and Scherer, 2015). The surplus FFAs 
undergo FA oxidation ultimately producing substrates that are responsible for the development of 
insulin resistant conditions such as impaired glucose uptake and glucose oxidation (Randle et al., 
1963). 
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7.1.2 Cardiovascular diseases 
Atherosclerosis is known to be a main risk factor for cardiovascular disease (Espach et al., 2015). A 
number of metabolic factors have been found to be associated with an increased risk for 
atherosclerosis of which hyperglycaemia and insulin resistance are two abnormalities also directly 
associated with T2D (King and Wakasaki, 1999). T2D is recognised as a metabolic state which 
aggravates underlying mechanisms in the development of atherosclerosis and heart failure. 
Atherosclerotic cardiovascular disease (ASCVD) is the main cause of mortality and disability 
amongst diabetic patients (Low Wang et al., 2016). Important indicators of ASCVD in T2D are 
coronary heart disease (advanced atherosclerosis), ischaemic stroke, peripheral artery disease and 
heart failure (Low Wang et al., 2016). Diabetic individuals have been found to have a high 
prevalence of coronary and peripheral artery disease; however the lowering of glucose levels has 
yet to show an improvement in cardiovascular event rates (reviewed in (Low Wang et al., 2016). 
T2D has a higher atherosclerotic plaque burden, higher percentage atheroma volume (the 
proportion of the total vessel wall volume occupied by atherosclerotic plaque) (Puri et al., 2013) 
and smaller lumen diameters in the coronary arteries when compared to non-diabetic individuals 
(Nicholls et al., 2008). Hyperglycaemia reduces endothelial function and decreases the availability 
of nitric oxide (NO) (Williams et al., 1998). The high blood glucose concentration promotes 
inflammation of macrophages and enhances further inflammatory responses (Nishizawa and 
Bornfeldt, 2012). In an experiment comparing constant hyperglycaemia to induced episodes of 
hyperglycaemia followed by normoglycaemia over a period of 24 hours, it was found that the 
induced episodes of hyperglycaemia followed by normoglycaemia decreased endothelial function 
and increased oxidative stress (Ceriello et al., 2008). Individuals with insulin resistance also 
experience increased rates of hypertension, dyslipidaemia and impaired glucose tolerance 
(Mikhail, 2009) which contribute to the development and progression of atherosclerosis (Low 
Wang et al., 2016).  
Endothelial function is weakened in both type I diabetes mellitus (T1D) and T2D (Johnstone et al., 
1993; Williams et al., 1996). Studies have found that a short period of exposure to high 
concentrations of glucose is enough to decrease the bioavailability of nitric oxide (NO), as 
reviewed by Low Wang et al. (2016). Endothelial dysfunction aids the development of thrombosis, 
adhesion of leukocytes and platelets and inflammation (Potenza, Addabbo and Montagnani, 
2009). During compensatory hyperinsulinaemic conditions there is an increased production of 
vasoconstrictors, angiotensin II and endothelin-1, which contribute to the development of 
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endothelial dysfunction and hypertension (Potenza et al., 2005; Sarafidis and Bakris, 2007; 
Kobayashi et al., 2008).  
ATM is activated by oxidative stress and DNA damage which are both associated with 
atherosclerosis (Espach et al., 2015). Studies have found that decreased ATM expression simulates 
clinical characteristics seen in the metabolic syndrome and some of these symptoms were 
ameliorated with anti-oxidants and ATM activators (reviewed by Espach et al., 2015). The c-Jun N-
terminal kinase (JNK) protein is responsible for the phosphorylation of Ser-307 of the insulin 
receptor substrate-1 (IRS-1), subsequently disrupting insulin signalling and aiding the development 
of insulin resistance (reviewed by Espach et al., 2015). Increased JNK activity was observed in the 
aorta, macrophages, adipose tissue, skeletal muscle and liver of ATM deficient mice (Schneider et 
al., 2006). Furthermore, JNK1 deficient mice were protected from developing insulin resistance 
and obesity (Hirosumi et al., 2002). Activator protein-1 (AP-1) is a transcription factor, which can 
be activated by JNK, and plays a role in lipoprotein lipase expression which has been identified as a 
contributing factor to the development of atherosclerosis (Mead and Ramji, 2002; Schneider et al., 
2006). As reviewed by Espach and colleagues (2015), the ATM/p53 pathway is one of the 
mechanisms that aids the development of insulin resistance and atherosclerosis. A study 
investigating a drug for atherosclerosis, where wild-type mice were fed a high fat diet, mice were 
found to have decreased atherosclerosis, however in mice deficient of p53 there were no effects, 
confirming that the benefits from ATM activity relied on the presence of p53 (Razani, Feng and 
Semenkovich, 2010). ATM phosphorylates p53 at Ser-15 in humans and Ser-18 in mice, where a 
mutation in mice caused an increase in inflammation cytokine expression and a decrease in 
antioxidant expression (reviewed by Espach et al., 2015). Furthermore, these mice developed 
glucose intolerance and insulin resistance at 6 months and the researchers hypothesised that the 
accumulation of oxidative damage disrupted glucose homeostasis (Armata et al., 2010). As 
reviewed by Espach et al. (2015), due to the short average life span of AT patients, they do not live 
long enough to see the problematic effects of deficient functional ATM expression on the 
cardiovascular system. However, in a personal communication from Prof Y Shiloh (Israel) who has 
a large base of AT patients, his patients all suffer from ischaemic heart disease (unpublished data). 
Defective ATM signalling has been found to cause symptoms similar to that of the metabolic 
syndrome, which is a contributing condition to cardiovascular disease (Espach et al., 2015). Ten to 
forty percent of the heart’s energy originates from glucose metabolism under ischaemic heart 
conditions, the heart mainly uses glucose for energy. Under normal conditions however, the 
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heart’s main energy source is lipids (Gertz et al., 1988; Taegtmeyer, 2000). Espach et al. (2015) 
proposes that abnormal glucose metabolism would visibly affect cardiovascular function, which 
would be more prominent during ischaemia, and as ATM has a role in glucose metabolism and 
insulin signalling pathways, the deficiency of ATM may aggravate cardiovascular dysfunction. 
7.1.3 Metabolic syndrome 
Metabolic syndrome or syndrome X consists of a group of disorders that occur simultaneously 
(Samson and Garber, 2014). A number of studies were done to define metabolic syndrome. The 
definitions differed but all agreed on the components of abdominal obesity or overall obesity, 
impaired glucose metabolism, hypertension and dyslipidaemia being the most common 
characteristics of metabolic syndrome (Samson and Garber, 2014). However, epidemiological 
studies found that not all patients with metabolic syndrome were insulin resistant (Mikhail, 2009). 
Insulin resistance is a characteristic that contributes to a number of other characteristics seen in 
metabolic syndrome such as, hyperglycaemia, dyslipidaemia and obesity (Mikhail, 2009).  
In the early development of insulin resistance, β cells of the pancreas increase the secretion of 
insulin causing hyperinsulinaemia to maintain normal blood glucose levels (euglycaemia). 
However, when the degree of insulin resistance increases, the β cells are unable to secrete 
sufficient insulin according to the body’s physiological demands, subsequently developing glucose 
intolerance and hyperglycaemia (Mikhail, 2009). Hyperinsulinaemia and hyperglycaemia may 
further contribute to the symptoms seen in metabolic syndrome as they can further aggravate 
insulin resistance. Insulin suppresses lipolysis under normal physiological conditions (Eckel, Grundy 
and Zimmet, 2005) however, insulin resistance promotes the lipolysis of adipose tissue and the 
release of FFAs into circulation (Mikhail, 2009) (as discussed in Section 6.1.1b). A common 
characteristic of metabolic syndrome dyslipidaemia is the modifications in lipoprotein composition 
which often occur during hypertriglyceridaemia, leading to an increase of low-density lipoproteins 
(LDL) and a decrease of high-density lipoproteins (HDL) in circulation (Eckel, Grundy and Zimmet, 
2005). Obesity is considered as a contributing factor to the development of hypertension, 
dyslipidaemia and insulin resistance seen in metabolic syndrome, however, studies have found 
that obesity alone cannot be the cause for all the symptoms seen in metabolic syndrome and that 
other factors are contributing to this disease (Mikhail, 2009). 
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7.1.4 NAFLD 
NAFLD is the most common liver disease internationally (Pala et al., 2014) and is the general 
diagnostic term used for a spectrum of liver pathologies ranging from non-alcoholic fatty liver to 
non-alcoholic steatohepatitis, cirrhosis, fibrosis and hepatocellular carcinoma (Olaywi et al., 2013).  
NAFLD is commonly present with other characteristics found in metabolic syndrome, namely 
obesity and insulin resistance (Paniagua et al., 2014) and, vice versa, insulin resistance is present in 
these liver pathologies (Pala et al., 2014). Although the underlying mechanism is not fully 
understood, it is suggested that insulin resistance induces triglyceride and FFA accumulation in the 
liver, stimulating oxidative stress and the release of pro-inflammatory cytokines causing injury of 
hepatocytes (Mazza et al., 2012). The hallmark characteristic of NAFLD occurs when the rate of 
liver fatty acid uptake from circulation and de novo fatty acid synthesis are more than the rate of 
fatty acid oxidation and exportation (Fabbrini, Sullivan and Klein, 2010). According to Paniagua et 
al. (2014), it has become more evident that NAFLD patients have dysfunctional adipose tissue, 
especially a decrease in disposal and storing of fatty acids as well as an increase in peripheral 
adipose tissue lipolysis and irregular adipocytokine secretion, which they propose to have a direct 
impact on the development of liver insulin resistance and NAFLD. 
A study by Paniagua et al. (2014) investigated transcriptional changes in adipose tissue of NAFLD 
patients as a function of their insulin resistant status, as well as the transcriptional acute response 
of adipose tissue genes to dietary and insulin treatments in the cohort of participants with the 
highest insulin resistance. The study found that, after multiple comparisons, only the messenger 
ribonucleic acid (mRNA) of leptin expression was significantly decreased in white adipose tissue of 
insulin resistant participants, when compared to that of the insulin sensitive participants. The 
mRNA expression correlated with leptin serum levels and was decreased irrespective of the higher 
body weight of insulin resistant participants. It was also found that, for energy intake, the ratio of 
monounsaturated fatty acids (MUFA) to saturated fatty acids (SAT) were lower in insulin resistant 
than the insulin sensitive participants. The study was unable to conclude that the liver enzyme 
profiles could be used to segregate patients according to insulin sensitivity as there were no 
differences between insulin resistant and insulin sensitive participants. However, it was concluded 
that insulin sensitivity is directly linked to adiponectin levels and higher MUFA/SAT ratio intake 
and inversely to white blood cells in NAFLD individuals (white and red blood cells were found to be 
higher in insulin resistant participants).  
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7.1.5 PCOS 
PCOS is an endocrinopathy characterised by menstrual disorders, anovulatory infertility and 
increased levels of male hormones (Pasquali, Gambineri and Pagotto, 2006). It was reported that 
50 – 60% of PCOS patients suffer from insulin resistance (Dunaif et al., 1989; Legro, Finegood and 
Dunaif, 1998) and that this is due to their impaired insulin secretion (Dunaif et al., 1989). The 
impaired insulin secretion has an early onset risk of progressing to T2D which is earlier when 
compared to non-PCOS individuals (Dunaif et al., 1989). According to Azziz (2002), insulin 
resistance aids the development of compensatory hyperinsulinaemia, which appears to be a main 
factor in hyperandrogenism of PCOS. Hyperinsulinaemia stimulates ovarian theca androgen 
secretion, acanthosis nigricans (excess growth and discolouration of skin basal cells) and 
dysfunctional liver and peripheral lipid metabolism (Azziz, 2002). Insulin sensitising medication has 
been found to improve clinical characteristics in PCOS patients, suggesting insulin resistance and 
hyperinsulinaemia as the underlying cause for many of PCOS’ characteristics (Azziz, 2002).   
A study by Park et al. (2001) compared the insulin resistance between controls, obese with T2D 
and PCOS women. No statistical significance was seen between the groups’ age, waist to hip ratio 
(WHR), BMI, body fat, lipid profile and ideal body weight. However, basal serum insulin levels were 
found to be higher and statistically significant in the PCOS group along with higher luteinizing 
hormone (LH) and testosterone levels and lower sex hormone binding globulin (SHBG). The study 
concluded that PCOS women were insulin resistant independent of adiposity (Park et al., 2001). In 
a study by Brower et al. (2013) the relationship between the severity of menstrual dysfunction and 
insulin resistance in PCOS patients were investigated, where the homeostasis model assessment 
for insulin resistance (HOMA-IR) was used to measure the degree of insulin resistance. PCOS 
individuals with menstrual cycles longer than 35 days had a mean HOMA-IR significantly higher 
than that of the controls and individuals with the highest HOMA-IR levels were those with a 
menstrual cycle longer than 3 months (Brower et al., 2013).  
7.1.6 Cancer  
A study by Steinberger et al. (2012) found that childhood cancer survivors (CCS) are more insulin 
resistant and have higher levels of cardiovascular risk factors when compared to their healthy 
sibling before reaching adulthood. In this study childhood cancer survivors in remission for at least 
5 years between the ages of 9 and 18 years were recruited along with age-matched controls that 
have never had cancer. The participants underwent extensive measuring of parameters to 
determine body fat composition, insulin resistance and insulin sensitivity. The study found that 
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CCS had a lower level of insulin sensitivity and suggested these lower levels may influence the 
early increase in cardiovascular risk factors and that the difference between the CCS and controls, 
risk factor levels will become more apparent with age (Steinberger et al., 2012).   
A review article reported on a meta-analysis of a number of studies performed in different 
countries focusing on the association between factors related with insulin resistance and cancer 
risk. The analysis showed the risk per 5 kg/m2 increase in BMI with a calculated relative risk (RR) 
for cancers of the oesophagus (RR = 1.5), thyroid (RR = 1.3), colon (RR = 1.2), kidney (RR = 1.2) and 
liver (RR = 1.2) in men and cancers of the endometrium (RR = 1.6), gallbladder (RR = 1.6), 
oesophagus (RR = 1.5) and kidney (RR = 1.3) in women (Inoue and Tsugane, 2012). This suggests a 
relationship between an increase in BMI and the prevalence of developing cancer.  
8. Cancer and AT 
The ATM gene is also known as a tumour suppressor gene and is considered a breast cancer 
predisposition gene (Foroughizadeh et al., 2012). AT patients have a number of clinical 
characteristics, one of which is the predisposition for developing cancer (Foroughizadeh et al., 
2012). ATM’s main known functions are to repair DSBs in the DNA and to control signalling 
pathways of cell-cycle checkpoints (Foroughizadeh et al., 2012). The hallmarks of cancer include 
sustaining proliferation, avoiding growth suppressors and immune destruction, allowing unlimited 
cell proliferation (replicative immortality), resisting cell death, tumour-promoting inflammation, 
deregulating cellular energetics, instability and mutations of the genome, activation of invasion 
and metastasis and inducing angiogenesis (Hanahan and Weinberg, 2011). As ATM repairs breaks 
in DNA and regulates signalling pathways of cell-cycle checkpoints, it could be suggested that the 
deficiency of ATM as observed in AT patients, would allow multiple genome mutations, as well as 
uncontrolled cell proliferation with abnormal cell-cycle checkpoint signalling increasing the 
probability of developing cancer. According to Foroughizadeh and colleagues (2012), females with 
a heterozygous AT gene have a fivefold increased risk of developing breast cancer when compared 
to the general population. Due to ATM’s function of desensitising the cell against genotoxic attacks 
(damaging to genetic material), AT patients are radiosensitive to ionising radiation and AT cancer 
patients receive a decreased dose of radiation in cancer treatment, as the normal doses used for 
non-AT cancer patients could be lethal (Khalil, Tummala and Zhelev, 2012). According to Khalil et 
al. (2012) a number of cancers have an established link to ATM with cancer been the most 
frequent cause of death in AT patients. As one of the characteristics of AT individuals is a feeble 
immune system, the most common forms of cancers they develop are of the immune system, 
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namely lymphomas and leukaemias with non-Hodgkin’s lymphoma and acute lymphocytic 
leukaemia being the most common (Khalil, Tummala and Zhelev, 2012). Cancers of the immune 
system are common in young AT patients, however, older AT patients have a higher predisposition 
of developing malignancies in other organ systems such as (i) breast, (ii) stomach, (iii) brain 
(known as a medulloblastoma) and (iv) the skin (basal cell carcinoma which is a type of skin cancer 
of the basal cells) (Meyn, 1999). According to Khalil et al. (2012), leukaemias were found to be of T 
cell origin and lymphomas of B cell origin. B and T cells are lymphocytes and form part of white 
blood cells circulating in the blood throughout the body.  
9. Peripheral blood mononuclear cells 
9.1 Genetic material 
Blood constantly circulates around the body connecting all biological systems at a physiological 
level and is defined as a fluid connective tissue consisting of cells suspended in a fluid matrix (Liew 
et al., 2005). Blood contains white blood cells namely, neutrophils, monocytes, lymphocytes (B 
and T cells), basophils and eosinophils, which form part of the first line of defence in the immune 
system (Liew et al., 2005). Peripheral blood mononuclear cells (PBMCs) are white blood cells 
consisting of monocytes and lymphocytes (Reynés et al., 2016) which contain a single round 
nucleus with DNA found to express approximately 80% of the human genome when compared to 
other tissues (Liew et al., 2005). Because they express a large percentage of the genome, PBMCs 
can be used for genetic analysis in comparison to more invasive sampling of other tissues (Reynés 
et al., 2016). This circulating blood cells’ gene expression varies amongst persons from which a 
gene expression profile can be constructed. Changes in these gene expression profiles were found 
to be characteristic of a number of diseases and disorders (Tsuang et al., 2005).  
9.2 Environmental stimuli of gene expression 
According to Reynés et al. (2016) PBMCs gene expression can reflect the metabolic effects of 
different diets, such as high-fat diets, with reference to the digestion of lipids and cholesterol 
specifically. These researchers also found that obesity and T2D affect PBMCs’ gene expression of 
certain cytokines (Reynés et al., 2016). This may also be affected by outside stimuli such as 
exercises and smoking (Liew et al., 2005).  Thus the gene expression profiles of PBMCs can be used 
as an indication of its micro- and macro-environment (Liew et al., 2005). 
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9.3 Gene expression profiles 
Gene expression profiles are compiled following the isolation of PBMCs from whole blood by 
centrifugation with a density gradient medium. DNA and RNA are extracted from the PBMCs using 
commercially available reagents and a gene expression profile is constructed using microarray 
analysis and real time reverse transcription polymerase chain reaction (RT-PCR) (Jung et al., 2016). 
The gene expression profiles obtained from PBMCs are considered indicative of the physiological 
conditions of organs due to blood’s constant contact with certain areas in the body (Reynés et al. 
2016). According to Liew et al. (2005) a number of studies have found that alterations in these 
gene expression profiles may be used as a diagnosing indicator for a number of diseases such as 
hypertension, arthritis, lupus and cancer as well as variations in gene expression when exposed to 
external stimuli such as smoking, exercises or other forms of stress. Interestingly, a study 
conducted by Tsuang et al. (2005) demonstrated that psychiatric disorders also alter the gene 
expression profiles in PBMCs. A number of researchers suggest the use of PBMCs’ gene expression 
for the prognosis and diagnosis of certain diseases as the sampling of this tissue is less invasive 
and can be collected more frequently and in larger quantities than liver or lung biopsies (Liew et 
al., 2005; Reynés et al., 2016).  
9.4 Gene expression for diagnostics 
According to Reynés et al. (2016) the analysis of gene expression in PBMCs has become an 
important technique for investigations into the interactions between nutrition and genetics 
(nutrigenomics). As previously mentioned, the metabolic effects of diets high in lipids and 
cholesterol (hyperlipidic) were found to alter PBMCs’ gene expression, specifically from altered 
cholesterol metabolism, lipid metabolism and the inflammatory responses (Reynés et al., 2016). 
Reynés and colleagues (2016) mentioned studies that found PBMCs are susceptible to specific 
nutrients such as polyunsaturated fatty acids (PUFA) and polyphenols as well as changes in feeding 
conditions. A study was conducted where obese Spanish boys between the ages of 7 and 15 years, 
were fed a moderate energy restriction diet, after which baseline anthropometric measurements 
were compared to measurements following intervention (Rendo-Urteaga et al., 2015). The 
participants’ response to the intervention was measured according to their changes in BMI 
standard deviation score (BMI-SDS) and divided into low responding (LR) and high responding (HR) 
groups. Rendo-Urteaga et al. (2015) found that the HR group had lower levels of inflammatory and 
immune response-related genes compared to LR. It was hypothesised that the LR group may have 
a more developed pro-inflammatory phenotype (Rendo-Urteaga et al., 2015). Following the 
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intervention the LR group was found to have an overexpression of genes involved in cell 
proliferation, motility, survival, differentiation, haemostasis, immune response and inflammation. 
Obese individuals have been found to be in a constant pro-inflammatory state (Xu et al., 2003) and 
researchers have found that PBMCs’ gene expression of inflammatory cytokines are affected in 
obese and diabetic conditions (Tsiotra et al., 2007, 2008).   
10. Ageing 
10.1 Ageing and DNA damage and repair 
DNA is constantly susceptible to injury by various agents. Damaged DNA can accumulate and aid 
the generation of errors in DNA replication and mutations, which is thought to contribute to 
ageing, cancer development and neurodegeneration (Jeppesen, Bohr and Stevnsner, 2011). 
Depending on the type of DNA damage one of four repair pathways are activated namely, base 
excision repair (BER), nucleotide excision repair (NER), mismatch repair or DSBR (Garm et al., 
2013). DSBs are considered the most dangerous type of DNA lesion as it can cause genome 
rearrangements, however this type of lesion is not as common as single-strand breaks (SSBs) 
(Garm et al., 2013). DSBR is molecularly switched on by phosphorylation causing DSB formation 
followed by gamma phosphorylation (Ser-139) of the histone 2A (H2AX), now γ-H2AX (Garm et al., 
2013).  In the first hour following DSB formation γ-H2AX surrounds the break and is involved in 
DSB signalling response (Muslimovic et al., 2008). Several other DSB damage response proteins are 
activated downstream and subsequently affects DNA repair, cell cycle checkpoints, telomere 
maintenance and transcription (Garm et al., 2013). Following DSB, DSBR occurs via two 
mechanisms namely, non-homologous end joining (NHEJ), which works throughout the cell cycle, 
and homologous recombinational repair (HRR), which repairs DSBs at phases S and G2 of the cell 
cycle (Garm et al., 2013). 
Studies regarding single-strand break repair (SSBR) in PBMCs from donors of different ages, 
showed little or no effect of age, however other studies have suggested age-associated increases 
of SSBs in human PBMCs while others have reported no age effect (reviewed in (Garm et al., 
2013)).  A number of studies in human PBMCs and age-related NHEJ function found a decrease in 
binding of a specific complex and Garm et al. (2013) proposed these studies suggest changes in 
DNA repair with age. As PBMCs and blood cells are frequently replaced it was suggested that it 
may not be as susceptible to ageing as organ cells (Garm et al., 2013), however, old age has been 
associated with age-associated decreases in immune repertoire and function (Gill, Rutherfurd and 
Cross, 2001). Garm et al. (2013) reviewed a number of studies looking at DNA repair and its 
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association with age and reported that some studies found there is a decrease in the ability to 
repair DNA damage with the progression in age. The results of Garm and colleagues (2013) 
suggested that SSB repair ability can be maintained up to the age of 77 in human PBMCs. 
Additionally, no statistical significance was seen for age-related changes in endogenous SSBs, 
however, the results suggested a tendency of DSBR and γ-H2AX response to decline with age but 
none of the associations were statistically significant. 
10.2 Premature ageing in AT 
Multiple similarities have been seen between elderly patients and AT patients with regards to 
clinical, pathological and the CNS effects, and AT has been proposed as a premature ageing model 
(Boder E., 1985). AT patients also have multiple defects of the immune system and this has been 
suggested to be indicative of premature ageing of the immune system in AT individuals (Exley et 
al., 2011; Carney et al., 2012). AT was proposed as a model for the ageing of the immune system 
(Exley et al., 2011). Younger AT patients were found to have health problems normally related to 
people of middle to elderly age. A study on 53 AT patients, between the ages of 5.9 – 26.1 years, 
found that 43% had increased serum transaminase, 39% had fatty liver and 33% developed more 
severe liver diseases (Weiss et al., 2016) while another study found an increased incidence of 
dyslipidaemia and diabetes (Nissenkorn et al., 2016). Similarities were seen between brain 
function of aged individuals and AT individuals experiencing neurodegeneration (Barzilai, 
Schumacher and Shiloh, 2017). With the characteristic of premature ageing in AT, Shiloh and 
Lederman (2017) suggested that premature cell senescence may be responsible. Shiloh and 
Lederman (2017) defined the hallmark of cellular senescence as the irreversible arrest of cell 
proliferation. Cell senescence can be stimulated by a number of stresses and has been suggested 
as an important factor for development, wound healing, tissue repair and ageing (reviewed in 
(Shiloh and Lederman, 2017)). AT patients suffer from age-related abnormalities such as 
telangiectasia of the eye, length-dependent neuropathy causing foot deformation, cerebellar 
atrophy, intracerebral telangiectasia and cutaneous granulomas (Shiloh and Lederman, 2017).  
As previously discussed, ATM has multiple functions in pathways related to the cell cycle, cell-cycle 
check point regulation and cell proliferation, metabolism, DNA repair, transcription and protein 
degradation. The literature suggests the susceptibility of DNA repair to ageing and subsequently a 
possible decrease in bioavailability and/or expression of the ATM protein.  
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11. Motivation for this study 
Non-communicable diseases (NCDs) are increasing worldwide with 70% of all deaths been due to 
NCD in 2015 of which 4% was deaths due to T2D worldwide (World Health Organization, 2017). In 
NCD Country Profiles 2014 compiled by the World Health Organisation (WHO), it was reported for 
South Africa that approximately 43% of deaths were due to NCD of which the four main 
contributors were cancer (7%), T2D (6%), cardiovascular diseases (18%) and chronic respiratory 
diseases (3%) (WHO, 2014) which are linked to metabolic disorders such as insulin resistance, 
glucose intolerance, hyperinsulinaemia, obesity and dyslipidaemia.  
A recent study investigated the potential of ATM serine-1981 phosphorylation (ATM 1981S-P) as a 
biomarker for radiation, radiation toxicity and DNA damage (Bakkenist, Beumer and Schmitz, 
2015). These investigators stated that there is a need for a biomarker for radiation exposure 
following the release of radioactive material, a predictive biomarker for radiation toxicity following 
treatment for tumours (oncology) and pharmacodynamics biomarkers for chemotherapy related 
DNA damage and the inhibition of signalling kinases for DNA damage. A biomarker is a 
characteristic that can be measured and used as an indicator of normal physiological processes, 
pathological processes or a pharmacological response to a treatment (Bakkenist, Beumer and 
Schmitz, 2015). Bakkenist and colleagues (2015) found that ATM 1981S-P levels increased in 
PBMCs following cancer radiation treatment. A previous study found that ATM 1981S-P is induced 
in the genome of PBMCs following drug-induced DNA damage (Bakkenist et al., 2015). 
This review focused on literature discussing ATM and its role in insulin signalling and glucose 
metabolism due to the genetic link found between the glycaemic response and metformin 
treatment in type II diabetics (Zhou et al., 2011) along with the development of insulin resistance, 
T2D and cancer in AT individuals. Research in PBMCs and the compiling of gene expression profiles 
and its use in the diagnosis of diseases and as biomarkers of pathology were also discussed. The 
effects of ageing on genetic material were linked to the premature ageing characteristic seen in AT 
patients. From literature it is evident that a diagnostic technique is needed for the early diagnosis 
of insulin resistance as it is a common characteristic found in a number of other prevalent 
diseases. PBMCs’ ability to express the human genome makes it an easily available source of 
protein expression. As AT commonly presents with insulin resistance and an increased prevalence 
for developing T2D along with the results found by Zhou et al. (2011), linking the ATM gene and 
ATM protein to the glycaemic response, it could be a plausible target for determining a patient’s 
degree of insulin resistance. 
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Thus this study proposes ATM protein expression from PBMCs as a diagnostic technique which 
could be used as an indicator of the measure of insulin resistance or the propensity to develop 
T2D in patients. PBMCs are an eligible source of protein expression as the study by Bakkenist et al. 
(2015) proved ATM was present in PBMCs. As insulin resistance is common in a number of NCD, 
sufferers of these diseases would also benefit from this diagnostic technique. 
12. Aim and Objectives 
Aim: To determine whether a) PBMCs can be used to determine ATM levels in insulin resistant 
subjects and b) whether these levels can be used as a biomarker for peripheral insulin resistance. 
Animal study: 
Objective 1: Standardise a protocol to isolate PBMCs from rat blood. 
Objective 2: Isolate PBMCs from rat blood and determine the ATM expression levels using 
Western blotting and a total ATM specific antibody. 
Objective 3: Use the PBMCs isolated from insulin resistant obese rats and those of age-matched 
control rats to determine whether there is any difference in ATM expression.  
Human study: 
Objective 1: Analyse PBMCs from a biobank that was collected from a female Black Xhosa 
population spanning normal, obese and pre-diabetic (metabolic syndrome) subjects and correlate 
the expression of ATM with the measure of insulin resistance. 
Objective 2: Broaden the ethnicity of human subjects and collect and analyse samples from Mixed 
Race subjects. 
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CHAPTER 2: MATERIALS AND METHODS  
The investigation was divided into animal-based experiments and human-based experiments. The 
animal experiments were to (i) set up and optimise a protocol to isolate PBMCs, (ii) determine 
whether the ATM protein expression levels can be measured in these PBMCs; (iii) determine 
whether obesity changes the expression of ATM in PBMCs and (iv) to determine whether any 
changes of ATM expression in PBMCs reflect changes observed in the heart. Samples were 
analysed by means of Western blotting and statistical analysis was done to determine significance. 
1. Setting up of PBMCs isolation protocol in an animal model  
During the setting up of the protocol an existing protocol for the isolation of human PBMCs were 
used as a guide (protocol from Division of Endocrinology, Department of Medicine, Faculty of 
Medicine and Health Sciences at Stellenbosch University). This protocol made use of a density 
gradient medium Histopaque®-1077 at a density of 1.077 gram (g)/millilitre (mL). According to the 
product information it could be used for the separation of small volumes of blood to collect 
lymphocytes and mononuclear cells. 
1.1 Whole animal blood collection 
Blood samples were collected at random from male Wistar rats sacrificed for other laboratory 
experiments. Samples of at least 5 mL of whole blood were collected with a Pasteur pipette from 
the chest cavity following the removal of the heart. Blood was collected in a 10 mL K2 
Ethylenediaminetetraacetic acid (EDTA) blood collection tube (SG Vac, The Scientific Group). The 
tube was inverted a number of times to ensure that the blood mixed with the anticoagulant to 
prevent clotting.  
1.2 Percoll PLUS® as density gradient medium 
The separation of whole blood samples were attempted with Percoll PLUS® (density 1.130 g/mL) 
(GE Healthcare Life Sciences) which was available in the laboratory. Following separation, the 
medium was found to be too dense to allow separation of the blood. A Stock Isotonic Percoll (SIP) 
was prepared at a density of 1.07 g/mL, NaCl at a concentration of 1.5 Molar (M) and a density of 
1.058 g/mL was used to dilute the Percoll PLUS at a dilution ratio of 9 parts Percoll to 1 part 1.5M 
NaCl (GE Healthcare Life Sciences, 2014). Multiple separations were done with the SIP solution, 
however clarity of separations varied, possibly due to the centrifugation speed, especially the 
centrifuge speed of deceleration which disturbed the separated layers, causing them to mix 
(Figure 2.1). Another possible reason for unclear separations may have been due to the prepared 
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SIP not been the correct density. Separations were attempted using the slow start/stop option on 
the centrifuge (Eppendorf Centrifuge 5403) which produced more defined layers.  
1.3 Comparison between Percoll PLUS® and Histopaque®-1077 
Due to the variations in separation results, a comparison was made between Percoll PLUS® and 
Histopaque®-1077 (Sigma-Aldrich). The centrifugation times and speeds were used from the 
existing Human PBMCs Isolation protocol. For the separation of the blood, 4 mL of gradient 
medium was pipetted into a sterile 15 mL conical tube and 4 mL of whole rat blood was slowly 
pipetted on top of the gradient medium to prevent the two layers from mixing. The blood was 
centrifuged at 1850 rpm for 30 min at room temperature using the slow start/stop function. The 
separation done with Histopaque®-1077 was clearer than that done with the SIP preparation 
(Figure 2.1).   
1.4 Centrifugation optimisation 
Following the separation of the blood the buffy coat (white blood cells situated at the interface 
between the blood plasma and the Histopaque®) was then transferred with a Pasteur pipette to a 
new sterile 15 mL tube with 5 mL sterile Phosphate Buffered Saline (PBS) (137 millimolar (mM) 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 dissolved in 800 mL distilled water (dH2O), pH 
to 7.4 and final volume of 1 litre (L) with dH2O) and centrifuged at 1450 rpm for 10 min at the 
room temperature with the slow start/stop. The pellet formed following separation with 
Histopaque was bigger and contained less platelets than the separation done with the SIP. Thus 
Histopaque was used as the density gradient medium for the animal experiments along with the 
centrifuge settings, explained in the following paragraph. 
1.5 Centrifugation specifications 
For clear isolation of PBMCs, the specific settings used were 1850 rpm for 30 min at room 
temperature to separate blood into its layers. The buffy coat was washed with 5 mL PBS at 1450 
rpm for 10 min at room temperature to collect the pellet. 
1.6 Storage and preparation of samples for lysates 
Following collection of the buffy coat in the form of a pellet, the PBS was discarded. Rat PBMCs 
sample pellets were suspended and stored in 1 mL freezing medium (100 microlitres (µl) Dimethyl 
sulfoxide (DMSO), 200 µl Bovine Serum Albumin (BSA) (50 milligram (mg) dissolved in 1 mL dH2O) 
and 700 µl Dulbecco’s Modified Eagle’s Medium (DMEM)) in a 1.5 mL Eppendorf tube at - 20 
degrees Celsius (°C) overnight and then - 80°C until analysis. However, as samples were analysed 
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with the Western blotting technique, later samples were stored in 100 µl fresh lysis buffer (20 mM 
Tris-HCl (pH 7.4), 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 1 mM beta (β)-glycerophosphate, 2.5 
mM tetra-Na-Pirophosphate, 1 mM Na3VO4 (freshly prepared weekly, 0.018 g/10 mL), 50 
microgram (µg)/mL PMSF, 10 µg/mL Leupeptin, 10 µg/mL Aprotinin and 1%  
Triton X-100 in a solution of total 5 mL dH2O ) in a 1.5 mL Eppendorf tube at - 80°C. This volume 
was later reduced to 50 µl to increase the protein concentration of each sample.  
 
Figure 2. 1: Setting up of rat PBMCs isolation protocol. 1) Collected whole blood from rats into 
EDTA tubes. 2) Separated blood with Percoll PLUS® (1.130 g/mL). 3) Separated blood with SIP 
(approximately 1.07 g/mL) which produced differences in separation with the same SIP. 4) 
Compared separation with SIP (right) to Histopaque®-1077 (left). 5) Washed buffy coat with PBS to 
compare clarity of isolation. 6) Isolated multiple samples with Histopaque® to optimise isolation 
technique. 7) Stored samples in freezing medium (- 20°C overnight then - 80°C) or lysis buffer (-
80°C). 8) Optimised isolation of protein from freezing medium and lysis buffer stored samples for 
lysate preparation. 
1.7 Lysing cells for protein isolation 
A new set of samples were collected and separated using Histopaque-1077. Samples were stored 
in freezing medium and later the storage medium was changed to lysis buffer. For analysis of 
samples stored in the freezing medium, samples were thawed and centrifuged at 2000 relative 
centrifugal force (g) for 7 min at 4°C (Sigma 1-14K Microcentrifuge). The supernatant was 
aspirated and discarded without disturbing the pellet. Cells were washed with 1 mL PBS and 
centrifuged at 2000 x g for 7 min at 4°C. Supernatant was aspirated and 100 µl fresh lysis buffer 
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was added to each sample with ¼ - ½ scoop (depending on pellet size) of Zirconium oxide beads 
(0.15 millimetre (mm)) (NEXT Advance). The samples stored in lysis buffer had a scoop of beads 
added while still frozen and sealed with Parafilm® M Laboratory Film (Lasec). Samples were 
homogenised with a Bullet Blender® (NEXT Advance) for 1 min at speed 8 with 5 min rest on ice. 
This was repeated twice with a final rest period of 20 min. Samples were centrifuged at 15000 rpm 
for 20 min at 4°C and the supernatant was transferred to a new 1.5 mL sterile Eppendorf tube. The 
supernatants were stored at - 80°C. 
1.8 Bradford assay 
The Bradford assay (Bradford, 1976) is a protein determination assay and was used for the 
measuring of each samples’ protein concentration. BSA was used as the standard solution (1 in 4 
dilution of BSA stock solution in dH2O and further diluted to construct a standard curve from 5 to 
60 µg protein (Table 2.1). This was assayed in duplicate along with a blank of dH2O. The assay was 
set up using plastic tubes. 
Table 2. 1: The dilutions of the BSA stock solution for the different protein concentrations (in µg). 
 
The samples underwent a serial dilution where 10 µl of each sample was diluted with 90 µl dH2O 
to dilute the concentration of the detergents used in the lysis buffer as they may otherwise 
interfere with the assay. 10 µl of the diluted sample was further diluted with 90 µl dH2O. Samples 
were also assayed in duplicate. The assay was set-up as shown in Figure 2.2.  
 
Figure 2. 2:  Set up of BSA standards and dilution of samples for the Bradford assay. 
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A 1:4 dilution with dH2O of a Bradford stock solution (0.06 mM Coomassie Brilliant Blue G-250, 
95% ethanol and 50% volume/volume (v/v) phosphoric acid) was filtered through a double layer of 
Whatman® Qualitative 1 filter paper (Whatman Limited) and 900 µl was pipetted into each BSA 
standard tube and each sample. Colour was allowed to develop for 20 min (start timer when 
adding Bradford solution to first tube) after which the spectrophotometer (Spectronic® 20 
Genesys™) absorbance reading was set to 0 with the blank and then the optical density (OD) of 
each BSA standard and sample were determined at 595 nanometre (nm) wavelength.   
1.9 Protein determination calculations 
Microsoft Excel was used to calculate and construct a standard curve graph from the BSA 
standards’ absorbance readings. The equation of this line was used to calculate the µg of protein 
in each sample, taking the dilution of the samples into account. The samples were adjusted with 
lysis buffer to all contain the same amount of protein per volume unit. Following analysis of the 
samples, each sample was found to have very low protein concentrations and thus the lysis buffer 
volume was decreased to 50 µl for future sample collection to concentrate the samples. 
1.10 Preparation of lysate samples for Sodium Dodecyl Sulphate (SDS)-Polyacrylamide Gel 
Electrophoresis (PAGE) 
The lysates were mixed with a 2x concentrated Laemmli sample buffer (4% SDS, 20% glycerol, 10% 
2-Mercaptoethanol, 0.004% Bromophenol blue, 0.125 M Tris-HCl) (Laemmli, 1970) (prepared by 
mixing 850 µl sample buffer stock solution with 150 µl 2-Mercaptoethanol) in a 2:1 ratio. Samples 
were boiled for 4 min and then centrifuged for 6 seconds (s) to collect sample in the bottom of the 
Eppendorf tube. Aliquots of samples were made as samples are thawed and then boiled before 
been used for blotting. If the remaining volume of sample is frozen and then thawed for another 
experiment some of the proteins would denature when boiled again. Samples were then stored at 
- 80°C.  
1.11 Western blotting 
Western blotting is a separation technique used to separate a sample’s proteins according to size. 
In SDS-PAGE, the samples are denatured and the gel contains SDS. The protocol makes use of 
current that flows through the gel and separates the proteins according to their size and their 
electrical charge. A set of samples were collected for the optimisation of the Western blotting of 
lysates obtained from PBMCs. These samples were stored directly in 50 µl lysis buffer at - 80°C.  
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1.11.1 Positive control 
A positive control known to contain the proteins of interest was used in each experiment. The 
positive control was prepared from a freeze clamped heart harvested from a sacrificed control rat. 
A small piece of tissue, approximately 100 mg, was transferred to a lysate tube containing 700 µl 
lysis buffer (on ice). Tissue was homogenised with a SilentCrusher M homogeniser (Heidolph 
Instruments) at 20 rpm for 4 s with a rest period on ice before repeating. The lysate of the positive 
control’s protein concentration was calculated to contain 50 µg of protein per 15 µl volume per 
well. 
1.11.2 Casting of gels 
For the separation of the proteins in the samples, two 15-well, 7.5%, 0.75 mm thick 
electrophoresis mini gels with a 4% stacking gel (Table 2.2) were cast using a standard Bio-Rad 
mini Protean III system. The stain-free solution was added to ensure visibility of the proteins in the 
Bio-Rad ChemiDoc ™ system. The Tetramethylethylenediamine (TEMED) (Sigma Life Science) was 
added just before the solution was pipetted into the casts as it is responsible for gel 
polymerisation in combination with ammonium persulfate (APS). The running gel was pipetted 
into the cast and a layer of butanol was layered on top to enable a straight meniscus. The gel was 
allowed to set (at least 30 min) and the butanol was rinsed out with dH2O once the gel had set. 
TEMED was added to stacking gel mix and then pipetted into the cast after which the 15-well 
comb was inserted and allowed to set (at least 15 min). The comb was removed once gels have set 
and wells were rinsed with dH2O. 
Table 2. 2: The composition of the 7.5% running gel and the 4% stacking gel used for Western 
blotting. 
 
1.11.3 Protein separation 
Samples were allowed to thaw and then boiled for 4 min. Sample was centrifuged to collect in the 
bottom of the tube and to remove any particulate matter. The system for running the gel was 
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filled with running buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS). Using a Hamilton syringe 
(Hamilton Company) 15 µl of each lysate along with the positive control was loaded into the wells. 
A volume of 5 – 7 µl of a 31 – 460 kilodalton (kDa) molecular weight marker (HiMark™ Pre-Stained 
Protein Standard) (Thermo Fisher Scientific) was loaded into the first lane as an indicator for the 
size of the proteins. The system was run for 10 min at 100 volts (V) and 200 milliamperes (mA) and 
then for 50 min at 200 V and 200 mA until the Coomassie blue front reached the bottom of the 
gel. The running buffer was discarded and the gels were removed from the casts and kept in a 
transfer buffer specially modified for ATM. The transfer buffer composition: 25 mM Tris, 192 mM 
glycine and 20% (v/v) MeOH, for the transfer buffer modified for ATM contained half the amount 
of MeOH. The gel was exposed using the ChemiDoc™ XRS+ system (Bio-Rad) and the image saved. 
The proteins separated in the lanes are visible with the ChemiDoc™ due to the Stain-free solution 
(Aldrich Chemistry) used in the gel. 
1.11.4 Protein transfer 
For the protein transfer, the gel was allowed to swell in transfer buffer for approximately 15 – 30 
min to allow optimal transfer of large proteins. A transfer sandwich was made by stacking a 
sponge, 2 pieces of blotting paper, the gel with the molecular ladder on the right, a polyvinylidene 
difluoride (PVDF) Immobilon®-P Transfer Membrane (Merck Millipore Ltd), 2 pieces of blotting 
paper (chromatography paper, grade: FN 100, 195 g/m2, Lasec) and another sponge, after which 
the transfer cassette was closed and inserted into the transfer system. The transfer occurs from 
the cathode (-) to the anode (+) thus the current should pass through the gel containing the 
proteins to transfer them to the membrane. Both transfer sandwiches were inserted into the 
system and an ice pack was inserted to keep the system cool. The system was filled with transfer 
buffer. The system ran for 1 hour 30 min at 200 V and 200 mA and the ice pack was changed after 
45 min to ensure that the system remained cold. Once the transfer was completed, the buffer was 
collected to be reused and the membrane was collected and kept in Tris-buffered saline (TBS)-
Tween solution (10x dilution of TBS stock (200 mM Tris (pH7.6), 1.37 M NaCl) with 0.1% Tween 
20). The membrane was visualised with the ChemiDoc™ system and an image was saved. To fix the 
proteins to the membrane, it was dipped in methanol for 30 s and allowed to air dry.  
1.11.5 Visualisation of proteins 
The membrane was blocked with 5% milk (5 mL fat free milk diluted in 95 mL TBS-Tween) for 1 
hour on a lab rotator at room temperature. The membrane was then washed with TBS-Tween 
thrice for 5 min on a lab rotator. The ATM protein was probed for with total (T)-ATM and 
Stellenbosch University  https://scholar.sun.ac.za
 30 
 
phosphorylated (P)-ATM antibodies (Cell Signaling Technology). Primary antibodies were diluted in 
a Primary Antibody Signal Boost (Merck Millipore) in a ratio of 1:1000. Membranes were exposed 
to the antibody overnight on a lab rotator at 4°C. The next day, the membranes were removed 
from antibody and washed with TBS-Tween as in the previous wash. The membranes were treated 
with anti-rabbit immunoglobulin G (IgG), horseradish peroxidase (HRP)-linked antibody (Cell 
Signaling Technology) as secondary antibody in a ratio of 1:4000 in Secondary Antibody Signal 
Boost (Merck Millipore). Membranes were treated for 1 hour on a lab rotator at room 
temperature. Membranes were washed with TBS-Tween and treated with 1.5 mL of the Clarity™ 
Western ECL Substrates (Bio-Rad) reagents for 5 min before exposure in the ChemiDoc™ system. 
Following exposure, the protein bands became visible and an image was saved.  
1.11.6 Normalisation 
Normalisation was performed by comparing the total protein in each lane that was transferred to 
the PVDF membrane to the band intensity of that lane on the membrane treated with the specific 
antibody using the Image Lab™ Software (Bio-Rad). The software uses the first lane as the 
standard and compares all the other lanes to lane 1 and generates a normalisation factor (Figure 
2.3). The software generated an analysis table containing the normalisation factor and 
normalisation volume (intensity). The normalisation factor is the corrective value calculated by the 
software in comparison to lane 1. The normalisation volume (intensity) is then calculated by 
multiplying the original volume (intensity) of each lane by the normalisation factor and generating 
the value that is indicative of the amount of the specific protein in each band. The use of the 
ChemiDoc™ normalisation system corrects for possible unequal loading of samples and negates 
the use of a loading control such as β-tubulin. 
1.11.7 Statistical analysis 
The data from the Image Lab was exported to Microsoft Excel where the average of all control 
samples was calculated. The fold change relative to the control was calculated by dividing each 
normalisation volume (intensity) by the average of the control. This data was exported to 
GraphPad Prism 5 software where statistical analysis was performed by either a one-way analysis 
of variance (ANOVA) or a Student’s t-test  
All steps used during the optimisation of the Western blotting technique were used during all 
other blotting of samples. Modifications were made to the protocol where necessary. 
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Figure 2. 3: Normalisation. Top image depicts the gel showing the separated proteins. Transferred 
proteins are detected on the Stain Free Blot (bottom left) where lanes are detected for total lane 
protein. Chemiluminescent bands are detected from the antibody probed membrane and 
normalised (bottom right). 
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2. Animal study 
2.1 Diet treatment of animals 
Male Wistar rats were fed either a standard chow (control) or an obesogenic diet (od) (Table 2.3), 
to induce insulin resistance, for 16 weeks. The diet is sometimes referred to as a high-fat diet 
(HFD) as it induces obesity in the rats. The diet was started when animals were 6 weeks old. The 
original cohort contained 20 rats of which two died and two provided insufficient volumes of 
blood to do further experiments.  The final experimental animals were 7 Controls and 9 od animals 
(Figure 2.4).  
Ethical approval was obtained from the Research Ethics Committee: Animal Care and Use of 
Stellenbosch University (Number: SU-ACUD16-00080). Handling of animals were conducted 
according to the accepted standards as stipulated in the South African National Standard for The 
Care and Use of Animals for Scientific Purposes, South African Bureau of Standards (SANS 
10386:2008). 
Table 2. 3: Composition of standard chow and od diets. 
 Fat 
(g/100g) 
Cholesterol 
(mg/100g) 
% 
Proteins 
% Carbohydrates 
Sugar 
(g/100g) 
Kilojoules 
(kJ/100g) 
Control 4.8 3 17.1 34.6 6.6 1272 
od 11.5 13 8.3 42 24.4 1364 
 
2.2 OGTT 
The OGTT is used to determine an animal or patient’s level of insulin sensitivity. At 15 weeks, 
animals were fasted overnight and OGTTs were done. To ensure ethical handling, rats were 
injected with 0.1 ml Eutha-naze (53 mg/kg Sodium pentobarbitone) (Bayer Animal Health) for 
anaesthesia. A drop of blood was collected from a tail prick and basal glucose levels were 
measured with a hand held glucometer. Rats were gavaged with 1 g/kg sucrose each and blood 
glucose levels were monitored for 2 hours. Blood glucose levels were measured with a drop of 
blood from the same tail prick at 3, 5, 10, 15, 20, 25, 30, 45, 60, 90 and 120 min for each rat.  Rats 
were left to recover for 1 week before sacrificing at week 16 of the diet and 22 weeks of age. 
2.3 Sacrificing of animals and blood collection 
During the diet period, rats were weighed before been anaesthetised for sacrifice. Animals were 
anaesthetised with 160 mg/kg Sodium pentobarbitone (Eutha-naze). Rats were checked to be 
unresponsive by pinching the foot (pedal reflex) or touching the eyes. The non-fasting blood 
glucose levels were measured with a glucometer by means of a tail prick. The heart was removed 
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and snap frozen in liquid nitrogen. Blood was collected from the chest cavity and PBMCs were 
isolated and stored in 50 µl lysis buffer in marked Eppendorf tubes and stored at - 80°C until 
protein determination. Intraperitoneal (IP) fat was removed and divided into abdominal and 
epididymal fat depots and weighed. 
2.4 Bradford assay and Western blotting 
Protein determination was done using the Bradford assay protocol as described previously. A 
standard curve was constructed using BSA standards and the absorbance readings were taken to 
determine the µg of protein in each sample. The samples were used to make lysates containing 30 
µg of protein per 15 µl. All 16 samples were run simultaneously on a 26 well Bio-Rad Criterion™ 
TGX Stain-Free™ Precast Gel with a 4-20% gradient. The lysate prepared from the rat heart tissue 
was used as a positive control. The protocol used during Western blotting optimisation was used 
and T-ATM and P-ATM protein expression was investigated. As samples were run on one 
membrane, the membrane was first treated with T-ATM antibody and then stripped.  
 
Figure 2. 4: Overview of group divisions in animal experiments.  
2.5 Stripping of membrane and blocking 
The membrane was stripped by exposing it to two 5 min sessions of washing with dH2O followed 
by 7 min of washing with 0.2 M NaOH and followed by another two 5 min sessions of washing with 
dH2O, all on a lab rotator at room temperature. The membrane was blocked with 5% milk for 2 
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hours on a lab rotator at room temperature and then washed with TBS-Tween before been 
treated with P-ATM antibody. 
2.6 Comparison between 22-week and 12-week animals 
To investigate whether age (weeks) had a role in the protein expression levels of the ATM kinase 
protein, an additional 6 control Wistar rats (standard chow diet) were sacrificed at 12 weeks 
(young controls) (Figure 2.4). All 22 samples were run on a precast gradient gel along with the 
positive control. The membrane was probed with T-ATM antibody, stripped and then probed with 
P-ATM antibody. As the P-ATM bands were not visible following stripping the samples were run on 
a new gel and the membrane was specifically probed with P-ATM antibody. 
3. Human study 
3.1 Patient recruitment 
Patients were recruited by researchers in the Division of Endocrinology, Department of Medicine, 
Faculty of Medicine and Health Sciences at Stellenbosch University. The patients were recruited at 
Tygerberg Hospital, Cape Town and were a Western Cape female black Xhosa population aged ≤ 
45 years (Ethics # N15/07/066 (PI: Dr M van de Vyver)).  
 
Figure 2. 5: Overview of group divisions for the human experiments.  
3.2 Biometric measurements and calculations 
Patients’ age (years), weight (kg), height (m) BMI (kg/m2), hip and waist measurements (cm), WHR, 
trunk:limb fat mass (TF/LF) (Dual energy X-ray absorptiometry (DXA), fasting blood glucose in 
millimoles per litre (mmol/L), total cholesterol (mmol/L), LDL (mmol/L), HDL (mmol/L), 
triglycerides (TAG) (mmol/L), systolic blood pressure (SBP) in millimetre of mercury (mmHg) and 
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diastolic blood pressure (DBP) (mmHg) were measured of each patient. The Atherogenic index was 
calculated for each patient according to the following formula: (total cholesterol – HDL)/HDL. HTR 
was calculated according to the following formula: HDL cholesterol/total cholesterol ratio and 
presented as a percentage. 
A risk score was calculated according to visceral adiposity, metabolic risk factors and inflammatory 
markers. Visceral adiposity: WHR ≥ 0.85, TF/LF > 1 was given a risk score of 0.5 and 1 respectively. 
Metabolic risk factors: TAG ≥ 1.7 mmol/L, HDL < 1.29 mmol/L, systolic blood pressure ≥ 130 mmHg 
and diastolic blood pressure ≥ 85 mmHg, fasting blood glucose ≥ 5.6 mmol/L each was given a risk 
score of 1, 1, 1 (0.5 for systolic and diastolic) and 1 respectively. C-reactive protein was measured 
as an inflammatory marker and where ≥15 mg/decilitre (dL) was given a risk score of 1. 
Patients were divided into groups for healthy lean with a risk score ≤ 1 (no visceral adiposity, one 
or no metabolic risk factors and normal BMI), overweight/obese with a risk score between 0-3.5 
(less than two metabolic risk factors and no visceral adiposity or normal BMI), metabolic syndrome 
with a risk score between 3-7 (more than two metabolic risk factors, visceral adiposity and 
previous diagnosis of type 2 diabetes (T2D)) and type 2 diabetics (previous diagnosis in medical 
history). For this study, healthy lean will be the controls, overweight/obese will be obese and 
metabolic syndrome will be pre-diabetic (Figure 2.5). The T2D samples did not form part of this 
study. 
3.3 Blood collection and PBMCs isolation 
Blood was collected as in the animal studies and separated by centrifugation. The PBMCs were 
collected and stored in 1 mL freezing medium (200 µl Human Serum Albumin (HSA), 100 µl DMSO, 
700 µl DMEM) at - 80°C. Samples were stored at - 20°C overnight and then stored at - 80°C. 
Human samples were collected from a biobank (made available by Dr Marí van de Vyver).   
3.4 Western Blotting 
3.4.1 Sample preparation 
In preparation for western blotting, samples were thawed and centrifuged at 2000 x g for 7 min 
and then an additional 4 min at 4°C to ensure all suspended cells were pelleted. The freezing 
medium was aspirated and the pellet was suspended in 100 µl ice cold PBS for washing. Samples 
were centrifuged 7 min at 4°C at 2000 x g. The supernatant was aspirated without disturbing the 
pellet and the pellet was suspended in 50 µl ice cold fresh lysis buffer (samples were kept on ice at 
all times). Zirconium beads were added according to the size of the pellets. Each Eppendorf tube 
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was sealed with Parafilm and put into the Bullet Blender®. Samples were homogenised as in the 
animal study before the supernatant (approximately 50 µl) were transferred to new tubes.  
3.4.2 Bradford assay 
The Bradford assay was modified due to the small pellet size and volume of each sample. For the 
1st dilution 5 µl sample was diluted in 45 µl dH2O instead of 10 µl in 90 µl dH2O. In the 2
nd dilution 
10 µl of the 1st dilution was diluted in 90 µl dH2O. The rest of the protocol was maintained as in 
the animal study. Bradford solution was prepared as previously explained and filtered. 900 µl was 
added to the BSA standards and dilutions of samples and colour was allowed to develop for 20 min 
before absorbance readings were taken at 595 nm. Protein concentrations were calculated in 
Microsoft Excel. All the samples’ protein concentrations were only sufficient to make lysates 
containing 15 µg of protein if 21 µl of the sample was loaded on the gel.  
3.4.3 Lysate protein concentration optimisation 
Due to the low protein concentrations, new PBMCs were isolated from rat whole blood. Lysates 
were prepared to contain 15 µg of protein. A standard 10 well 7.5% mini gel was cast and 21 µl of 
lysate was loaded on the gel as well as 25 µl (maximum volume of well) of the same sample along 
with 21 µl and 25 µl of the 50 µg positive control. This was to determine whether the difference in 
volume loaded would affect the band intensity. The gel was run and bands were normalised.  
3.4.4 Human protein separation 
Lysates containing 15 µg of protein were prepared from the human samples and 21 µl of each 
lysate was loaded for the groups: control (n= 8), obese (n= 9) and pre-diabetic (n= 7). Within each 
group data was split according to age with young being <30 years and middle aged (MA) been 30-
45 years. A lysate prepared from available mouse heart tissue was used as a positive control to 
load on gel.  Gel electrophoresis, protein separation and transfer to PVDF membranes were done 
according to the standard protocol as used in the animal study. T- and P-ATM was probed for and 
normalised according to the total lane protein.  
4. Western blotting of P22phox  
P22phox is a protein directly associated with NOXs and is used an indicator of the level of ROS 
production. As previously discussed under obese conditions, patients have low-grade 
inflammation. Inflammation enhances the production of ROS (Zhou et al., 2006; Hollyfield et al., 
2008) and the inhibition of P22phox was shown to decrease ROS generation, the activation of NOXs 
and inflammatory cytokine production (Qiu et al., 2015). Thus P22phox was probed for to 
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investigate inflammation and oxidative stress and whether there are any relationships with the 
degree of insulin resistance as well as the lipid profile. 
P22phox primary antibody was prepared in a 1:500 dilution in TBS-Tween with 1% milk. As P22phox is 
22 kDa, the bottom half of all animal and human study’s Western blotting membranes were 
probed for P22phox. 
5. Statistical analysis 
Normalisation of protein bands were done according to the total protein membrane and was done 
using Bio-Rad Image Lab™ software and data was exported to Microsoft Excel. Fold change 
relative to control was calculated in Microsoft Excel. Data was transferred to GraphPad Prism 5 
software where one-way ANOVA or two-way ANOVA (where applicable), Bonferroni’s Multiple 
Comparison Test and Student t Tests (where applicable) were performed. The data was used to 
construct column graphs with error bars and data was expressed as Mean ± Standard Error of the 
Mean (SEM). Analysis generating a p-value ≤ 0.05 was considered statistically significant. 
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CHAPTER 3: RESULTS 
This chapter reports the results of the animal and human PBMCs analysis. 
1. Animal study 
Rats were obtained at 6 weeks of age and fed an od diet to induce obesity and insulin resistance 
and compared to a normal standard chow-fed age-matched control for 16 weeks. Data collected 
was used to investigate the relationship between ATM levels and the degree of insulin resistance.  
1.1 Biometric data 
Body weight, IP fat mass, OGTT and basal blood glucose levels for controls, od and young control 
animals were measured. All data is expressed as Mean ± SEM. 
1.1.1 Body weight  
A significant difference in body weight (g) was seen between the young controls versus (vs.) the 
age-matched controls (302.00 ± 8.33; vs. 411.30 ± 19.08 g; n= 5-7) with a p<0.0001. No significant 
difference was seen between the body weight of the age-matched controls vs. od (411.30 ± 19.08 
vs. 456.90 ± 12.23 g; n= 7-9) rats following treatment with the different diets (Figure 3.1). 
 
Figure 3. 1: Body weight (g) of experimental groups at sacrifice. 
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1.1.2 IP fat mass 
IP fat mass was measured after sacrificing after 16 weeks of diet. A significant difference was seen 
between the IP fat mass (g) of od vs. control (25.62 ± 1.50 vs. 14.17 ± 1.43 g; n= 7-9), p<0.0001 
(Figure 3.2). 
 
Figure 3. 2: Mean IP fat mass (g) of od vs. age-matched controls after 16 weeks of diet treatment. 
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1.1.3 OGTT 
OGTTs were recorded in week 16 following overnight fasting. A two-way ANOVA was performed 
that indicated an overall significant difference between the blood glucose levels (mmol/L) of the 
controls and od following treatment of 16 weeks with the respective diets with p<0.0001, n= 12 
per group (Figure 3.3). A significant difference was seen between the area under the curve (AUC) 
of the od when compared to the age-matched controls (793.3 vs. 731.2), p<0.05, n= 12 per group. 
A two-way ANOVA with repeated measures was performed to determine significance in the OGTT 
(p<0.0001) and was expressed as Mean ± SEM (Table 3.1). No statistical significance was seen 
when comparing the mean ± SEM of the od to that of the controls for each time point, n= 12 per 
time point per group. 
 
Figure 3. 3: OGTT (mmol/L blood glucose) of controls vs. od measured at time periods 0 min, 3 min, 
5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 45 min, 60 min, 90 min and 120 min measured in 
week 15 after administration of 1 g/kg sucrose. 
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Table 3. 1: OGTT (mmol/L blood glucose) values of controls and od animals. 
Time (min) 
Mean ± SEM 
Control od 
0 5.21 ± 0.16 5.75 ± 0.16 
3 5.78 ± 0.24 5.87 ± 0.19 
5 6.19 ± 0.25 6.48 ± 0.30 
10 6.43 ± 0.18 7.34 ± 0.24 
15 6.89 ± 0.23 7.63 ± 0.24 
20 6.98 ± 0.12 7.60 ± 0.27 
25 6.74 ± 0.07 7.56 ± 0.25 
30 6.46 ± 0.13 7.38 ± 0.19 
45 6.18 ± 0.16 6.78 ± 0.19 
60 5.92 ± 0.18 6.81 ± 0.32 
90 5.93 ± 0.23 6.04 ± 0.19 
120 5.58 ± 0.11 5.78 ± 0.18 
Data expressed as Mean ± SEM 
  
Stellenbosch University  https://scholar.sun.ac.za
 42 
 
1.1.4 Basal blood glucose levels 
Following 16 weeks of treatment with the separate diets the basal fasting blood glucose levels 
were measured. A significant difference was seen between the basal blood glucose levels 
(mmol/L) of the od vs. controls (5.75 ± 0.16 vs. 5.21 ± 0.16 mmol/L); p<0.05, both with n= 12 
(Figure 3.4). 
 
Figure 3. 4: Baseline blood glucose levels (mmol/L) of fasted od vs. age-matched controls (at 0 min 
of OGTT) (in week 15). 
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1.2 Western blotting data 
1.2.1 ATM 
a) T-ATM levels 
No significant difference was seen between the levels of T-ATM when comparing the od (n= 9) to 
the age-matched controls (n= 7) (Figure 3.5).  
 
Figure 3. 5: T-ATM levels (Arbitrary Units) of od vs. age-matched controls. PC Positive control. 
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b) P-ATM levels 
No significant difference was seen between the levels of P-ATM when comparing the od (n= 9) to 
the age-matched controls (n= 7) (Figure 3.6). 
 
Figure 3. 6: P-ATM levels (Arbitrary Units) of od vs. age-matched controls. PC Positive control. 
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c) P-ATM/T-ATM ratio 
No significant difference was seen between the P-ATM/T-ATM ratios of the od (n= 9) vs. the age-
matched controls (n= 7) (Figure 3.7). 
 
Figure 3. 7: P-ATM/T-ATM ratio (Arbitrary Units) for od vs. age-matched controls. 
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1.2.2 Age comparison 
An age comparison was performed between the total and phosphorylated ATM protein levels of 
age-matched controls fed the control diet for 22 weeks of age and young controls fed the same 
diet for 12 weeks. 
a) T-ATM levels 
Significant difference was seen between the T-ATM protein levels of the young controls (n= 6) 
compared to age-matched controls (n= 7) expressed as Arbitrary Units (AU) (2.677 ± 0.6661 vs. 
1.000 ± 0.1925 AU; p= 0.025) (Figure 3.8). No significant difference was seen between the T-ATM 
protein levels of the od (n= 9) and age-matched controls. 
 
Figure 3. 8: T-ATM levels (Arbitrary Units) of age-matched controls (22 weeks) vs. young controls 
(12 weeks). PC Positive control. 
  
Stellenbosch University  https://scholar.sun.ac.za
 47 
 
b) P-ATM levels 
A significant difference was seen between the P-ATM levels of the young controls (n= 6) when 
compared to the age-matched controls (22 weeks) (n= 7) (0.4708 ± 0.1106 vs. 1.000 ± 0.1484 AU; 
n= 6-7; p= 0.018) (Figure 3.9). 
 
Figure 3. 9: P-ATM levels (Arbitrary Units) of age-matched controls (22 weeks) vs. young controls 
(12 weeks). PC Positive control. 
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c) p-ATM/T-ATM ratio 
Significant differences were seen between P-ATM/T-ATM ratio (Arbitrary Units) of od vs. age-
matched controls (0.51 ± 0.13; n= 9 vs. 1.25 ± 0.25 AU; n= 7-9) with p= 0.0127 and young controls 
vs. age-matched controls (0.43 ± 0.28; n= 6 vs. 1.25 ± 0.25 AU; n= 6-7) with p= 0.0476 (Figure 
3.10).  
 
Figure 3. 10: P-ATM/T-ATM ratio (Arbitrary Units) of groups. 
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2. Human study 
Female black Xhosa patients were recruited, data was collected and participants were divided into 
young and middle aged groups. Data was used to investigate the relationship between ATM levels 
and the degree of insulin resistance.  
2.1 Biometric measurements 
Biometric data was analysed within each experimental group namely, control (n= 8), obese (n= 9) 
and pre-diabetic (n= 7) as well as according to age groups of young (Y) (<30 years) and middle aged 
(MA) (30 – 45 years) within each group. 
2.1.1 BMI 
a) BMI vs. degree of insulin resistance.  
Significant differences were seen between the BMI (kg/m2) of the obese vs. control (39.04 ± 1.46 
vs. 21.35 ± 0.85; n= 8-9) and pre-diabetic vs. control (41.29 ± 1.30 vs. 21.35 ± 0.85; n= 7-8), 
p<0.0001 (Figure 3.11). 
 
Figure 3. 11: BMI (in kg/m2) vs. the degree of insulin resistance.  
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b) BMI vs. age groups vs. degree of insulin resistance. 
Significant differences were seen in the BMI (kg/m2) of the Y obese vs. the MA obese (35.25 ± 0.82 
vs. 42.07 ± 1.44; n= 4-5), p= 0.0064, as well as the Y pre-diabetic vs. the MA pre-diabetic (44.45 ± 
0.39; vs. 38.92 ± 1.354; n= 3-4), p=0.0196. Significant difference was seen between Y obese vs. Y 
control (35.25 ± 0.82 vs. 21.47 ± 1.12; n= 4-6), as well as Y pre-diabetic vs. Y control (44.45 ± 0.39 
vs. 21.47 ± 1.12; n= 3-6), both with a p<0.0001. Significant differences were seen between MA 
obese vs. MA control (42.07 ± 1.44 vs. 20.99 ± 1.09; n= 2-5), p= 0.0004, as well as the MA pre-
diabetic vs. the MA control (38.92 ± 1.35 vs. 20.99 ± 1.09; n= 2-4), p= 0.0011 (Figure 3.12). 
According to a two-way ANOVA age had an overall interaction with the degree of insulin resistance 
with a p=0.0005 as well as the degree of insulin resistance with a p<0.0001, n= 2-6. 
 
Figure 3. 12: BMI (kg/m2) vs. age vs. the degree of insulin resistance. 
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2.2.2 WHR 
a) WHR vs. degree of insulin resistance. 
Significant differences were seen between the WHR (cm) of the obese vs. the control (0.85 ± 0.011 
vs. 0.75 ± 0.016 cm; n= 8-9) as well as the pre-diabetic vs. the control (0.90 ± 0.016 vs. 0.75 ± 0.016 
cm; n= 7-8), p<0.0001 (Figure 3.13).  
 
Figure 3. 13: WHR (cm) vs. the degree of insulin resistance. 
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b) WHR vs. age groups vs. degree of insulin resistance. 
Significant differences were seen in the WHR (cm) of the Y obese vs. Y control (0.84 ± 0.01 vs. 0.75 
± 0.012 cm; n= 4-6), p= 0.0007, as well as the Y pre-diabetic vs. Y control (0.90 ± 0.010 vs. 0.75 ± 
0.012 cm; n= 3-6), p<0.0001 (Figure 3.14). According to a two-way ANOVA, the degree of insulin 
resistance had an overall significant effect with a p<0.0001, n= 2-6. 
 
Figure 3. 14: WHR (cm) vs. age vs. the degree of insulin resistance. 
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2.2.3 TF/LF 
a) TF/LF ratio vs. degree of insulin resistance. 
Significant differences were seen for TF/LF ratio (measured by DXA) between obese vs. control 
(1.07 ± 0.087 vs. 0.72 ± 0.056; n= 8-9), p= 0.0046, and pre-diabetic vs. control (1.15 ± 0.09 vs. 0.72 
± 0.056; n= 6-8), p= 0.0009 (Figure 3.15).  
 
Figure 3. 15: TF/LF ratio (measured by DXA) vs. the degree of insulin resistance. 
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b) TF/LF ratio vs. age vs. degree of insulin resistance. 
Significant difference was seen for the TF/LF ratio of the MA control vs. Y control (0.51 ± 0.07 vs. 
0.79 ± 0.041; n= 2-6), p= 0.015; Y obese vs. Y control (1.19 ± 0.21 vs. 0.79 ± 0.041; n= 3-6), p= 
0.032; Y pre-diabetic vs. Y control (1.28 ± 0.04 vs. 0.79 ± 0.041; n= 2-6), p= 0.0007;  MA obese vs. 
MA control (0.99 ± 0.065 vs. 0.51 ± 0.07; n= 2-5), p= 0.0086, and MA pre-diabetic vs. MA control 
(1.09 ± 0.12 vs. 0.51 ± 0.07; n= 2-4), p= 0.0356 (Figure 3.16). According to a two-way ANOVA, age 
had an overall significant effect with p= 0.0249 and degree of insulin resistance had an overall 
significant effect of p= 0.0004, n= 2-6. 
 
Figure 3. 16: TF/LF ratio (measured by DXA) vs. age vs. the degree of insulin resistance. 
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2.2.4 Lipid profile 
The total cholesterol, HDL, LDL and triglyceride levels were measured for each patient. Data was 
analysed according to the degree of insulin resistance as well as age groups within each degree of 
insulin resistance. 
a) Total cholesterol 
i) Total cholesterol vs. degree of insulin resistance. 
No significant difference was seen in the total cholesterol levels (mmol/L) of the obese (n= 9) and 
pre-diabetic (n= 7) groups when compared to the controls (n= 8) (Figure 3.17). 
 
Figure 3. 17: Total cholesterol levels (mmol/L) vs. the degree of insulin resistance. 
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ii) Total cholesterol vs. age vs. degree of insulin resistance.  
No significant differences were seen in the total cholesterol levels (mmol/L) when comparing age 
within each group or when comparing to the age controls, n= 6 for Y control, n= 2 for MA control, 
n= 4 for Y obese, n= 5 for MA obese, n= 3 for Y pre-diabetic and n= 4 for MA pre-diabetic (Figure 
3.18). 
 
Figure 3. 18: Total cholesterol levels (mmol/L) vs. age vs. the degree of insulin resistance. 
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b) LDL 
i) LDL cholesterol levels vs. degree of insulin resistance. 
No significant differences were seen between the LDL cholesterol levels (mmol/L) obese (n= 9) and 
pre-diabetic (n= 7) groups when compared to the controls (n= 8) (Figure 3.19). 
 
Figure 3. 19: LDL cholesterol levels (mmol/L) vs. the degree of insulin resistance. 
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ii) LDL cholesterol levels vs. age vs. degree of insulin resistance. 
No significant difference was seen in the LDL cholesterol levels (mmol/L) when comparing age 
within each group or when comparing to age controls, n= 6 for Y control, n= 2 for MA control, n= 4 
for Y obese, n= 5 for MA obese, n= 3 for Y pre-diabetic and n= 4 for MA pre-diabetic (Figure 3.20). 
 
Figure 3. 20: LDL cholesterol levels (mmol/L) vs. age vs. the degree of insulin resistance. 
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c) HDL 
i) HDL cholesterol levels vs. degree of insulin resistance. 
No significant differences were seen in the HDL cholesterol levels (mmol/L) of the obese (n= 9) or 
pre-diabetic (n= 7) groups when compared to the controls (n= 8) (Figure 3.21). 
 
Figure 3. 21: HDL cholesterol levels (mmol/L) vs. the degree of insulin resistance. 
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ii) HDL cholesterol levels vs. age vs. degree of insulin resistance. 
No significant difference was seen in the HDL cholesterol levels (mmol/L) when comparing age 
within each group or when comparing to age controls, n= 6 for Y control, n= 2 for MA control, n= 4 
for Y obese, n= 5 for MA obese, n= 3 for Y pre-diabetic and n= 4 for MA pre-diabetic (Figure 3.22). 
 
Figure 3. 22: HDL cholesterol vs. age vs. the degree of insulin resistance.  
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d) Triglycerides 
i) Triglyceride levels vs. degree of insulin resistance. 
No significant differences were seen in the triglyceride levels of the obese (n= 9) and pre-diabetic 
(n= 7) groups when compared to the controls (n= 8) (Figure 3.23). 
 
Figure 3. 23: Triglyceride levels (mmol/L) vs. the degree of insulin resistance. 
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ii) Triglyceride levels vs. age vs. degree of insulin resistance. 
Significant difference was seen for triglyceride levels (mmol/L) between the Y pre-diabetic and Y 
control (1.00 ± 0.26 vs. 0.56 ± 0.044 mmol/L; n= 3-6), p= 0.0479 (Figure 3.24). 
 
Figure 3. 24: Triglyceride levels (mmol/L) vs. age vs. the degree of insulin resistance. 
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2.2.5 Fasted blood glucose 
a) Fasted blood glucose levels vs. degree of insulin resistance.  
Statistical differences were seen for fasting blood glucose (mmol/L) of obese vs. control (5.10 ± 
0.21 vs. 4.41 ± 0.14 mmol/L; n= 8-9), p= 0.0170, as well as pre-diabetic vs. control (5.54 ± 0.23 vs. 
4.41 ± 0.14 mmol/L; n= 7-8), p= 0.0008 (Figure 3.25).  
 
Figure 3. 25: Fasting blood glucose levels (mmol/L) vs. the degree of insulin resistance. 
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b) Fasted blood glucose vs. age vs. degree of insulin resistance.  
Significant difference was seen between the Y pre-diabetic vs. Y control (5.90 ± 0.15 vs. 4.48 ± 0.13 
mmol/L; n= 3-6), p= 0.0003 (Figure 3.26). According to a two-way ANOVA, the degree of insulin 
resistance had an overall effect with p= 0.003, n= 2-6. 
 
Figure 3. 26: Fasting blood glucose levels (mmol/L) vs. age vs. the degree of insulin resistance. 
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2.2.6 Blood pressure, Atherogenic Index and HTR 
A significant difference was seen between the pre-diabetic vs. control with reference to SBP 
(mmHg) (136.1 ± 8.57 vs. 108.4 ± 4.47 mmHg; n= 7-8; *p<0.05), DBP (mmHg) (88.71 ± 2.48 vs. 
68.38 ± 2.53 mmHg; n= 8-9; ***p<0.0001) and HTR (30.14 ± 2.84 vs. 40.60 ± 3.78; n= 7-8; 
*p<0.05). A significant difference was seen between obese vs. control for Atherogenic Index 
(2.416 ± 0.26 vs. 1.62 ± 0.26; n= 8-9; *p<0.05). No significant differences were seen between 
obese vs. control for SBP, DBP or HTR as well as for Atherogenic Index for pre-diabetic vs. control 
(Table 3.2). 
Table 3. 2: SBP, DSP, HTR and Atherogenic Index according to the degree of insulin resistance of 
human study participants. 
 
Mean ± SEM 
Control (n= 8) Obese (n= 9) Pre-diabetic (n= 7) 
SBP (mmHg) 108.4 ± 4.47  121.3 ± 4.32 136.1 ± 8.57 * 
DBP (mmHg) 68.38 ± 2.53 76.56 ± 3.20 88.71 ± 2.48 *** 
HTR 40.60 ± 3.78 31.02 ± 2.92 30.14 ± 2.84 * 
Atherogenic Index 1.62 ± 0.26 2.416 ± 0.26* 2.50 ± 0.33 
 
* (p<0.05), *** (p<0.0001). Data expressed as mean ± SEM. Systolic blood pressure (SBP), diastolic 
blood pressure (DBP), HDL cholesterol/total cholesterol ratio (HTR). 
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Statistical significance was seen for SBP of MA pre-diabetic vs. MA control (149.0 ± 8.54 vs. 107.0 ± 
3.00 mmHg; n= 2-4; * p<0.05). According to a two-way ANOVA age (p= 0.0405) and the degree of 
insulin resistance (p= 0.0145) had an overall effect on SBP. Statistical significance was seen for DBP 
between Y obese vs. MA obese (68.00 ± 2.94 vs. 83.40 ± 2.31 mmHg; n= 4-5; ** p<0.01), Y pre-
diabetic vs. Y control (84.33 ± 4.84 vs. 70.17 ± 2.96 mmHg; n= 3-6; *p<0.05), MA obese vs. MA 
control (83.40 ± 2.31 vs. 63.00 ± 3.00 mmHg; n= 2-5; ** p<0.01) and MA pre-diabetic vs. MA 
control (92.00 ± 1.16 vs. 63.00 ± 3.00 mmHg; n= 2-4; ***p=0.0003). According to a two-way 
ANOVA the degree of insulin resistance had an overall effect, p<0.0001, on DBP. No significant 
differences were seen in HTR or Atherogenic Index (Table 3.3).  
Table 3. 3: SBP, DSP, HTR and Atherogenic Index according to the degree of insulin resistance and 
age of human study participants. 
 
Mean ± SEM 
Control Obese Pre-diabetic 
Y (n= 6) MA (n= 2) Y (n= 4) MA (n= 5) Y (n= 3) MA (n= 4) 
SBP 
(mmHg) 
108.8 ± 
6.05 
107.0 ± 
3.00 
114.3 ± 
3.07 
127.0 ± 
6.59 
119.0 ± 
10.54 
149.0 ± 
8.54 * 
DBP 
(mmHg) 
70.17 ± 
2.96 
63.00 ± 
3.00 
68.00 ± 
2.94 
83.40 ± 
2.31**,** 
84.33 ± 
4.84 * 
92.00 ± 
1.16*** 
HTR 39.25 ± 
4.78 
44.67 ± 
5.87 
32.39 ± 
2.82 
29.93 ± 
5.03 
28.18 ± 
6.02 
31.61 ± 
2.89 
Atherogenic 
Index 
1.736 ± 
0.33 
1.278 ± 
0.30 
2.161 ± 
0.28 
2.620 ± 
0.42 
2.847 ± 
0.71 
2.241 ± 
0.28 
 
*(p<0.05), ** (p<0.01), *** (p<0.001). Data expressed as mean ± SEM. Systolic blood pressure 
(SBP), diastolic blood pressure (DBP), HDL cholesterol/total cholesterol ratio (HTR), young (Y), 
middle aged (MA). 
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2.2 Western blotting data 
2.2.1 15 µg animal PBMCs optimisation 
The human PBMCs samples were found to contain low concentrations of protein. Human PBMCs 
lysates could only be prepared with 15 µg of protein. A rat PBMCs lysate was prepared at the same 
concentration and tested to see if the protein bands would be visible. Sample was visible at 15 µg 
concentration and was compared to a positive control at 50 µg. 
2.2.2 ATM 
a) T-ATM levels 
No significant differences were seen in the T-ATM levels of the human PBMCs samples from the 
obese (n = 9) and pre-diabetic (n= 7) groups when compared to the control (n= 8) (Figure 3.27). 
 
Figure 3. 27: T-ATM levels (Arbitrary Units) vs. the degree of insulin resistance. PC Positive control. 
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b) P-ATM levels 
Significant differences were seen in the P-ATM levels of the human PBMCs samples from the 
obese vs. control (2.10 ± 0.41 vs. 1.00 ± 0.15 AU; n= 8-9), p= 0.0310, as well as the pre-diabetic vs. 
control (2.52 ± 0.62 vs. 1.00 ± 0.15 AU; n= 7-8), p= 0.0261 (Figure 3.28). 
 
Figure 3. 28: P-ATM levels (Arbitrary Units) vs. the degree of insulin resistance. PC Positive control. 
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c) P-ATM/T-ATM ratio 
No significant difference was seen between the P-ATM/T-ATM ratios of the human PBMCs 
samples when comparing obese (n= 9) or pre-diabetic (n= 7) groups to the control (n= 8) (Figure 
3.29). 
 
Figure 3. 29: P-ATM/T-ATM ratio (Arbitrary Units) vs. the degree of insulin resistance. 
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2.2.3 Comparison between Y and MA participants 
a) T-ATM levels 
No significant differences were seen in T-ATM levels when comparing age within degree of insulin 
resistance (Figure 3.30), with n= 6 for Y control, n= 2 for MA control, n= 4 for Y obese, n= 5 for MA 
obese, n= 3 for Y pre-diabetic and n= 4 for MA pre-diabetic. 
 
Figure 3. 30: T-ATM levels (Arbitrary Units) vs. age vs. the degree of insulin resistance. PC Positive 
control, Y Young, MA Middle aged. 
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b) P-ATM levels 
Significant difference was seen in P-ATM levels between the Y pre-diabetic vs. the Y control (2.09 ± 
0.55 vs. 1.03 ± 0.17 AU; n= 3-6), p= 0.0458 (Figure 3.31). 
 
Figure 3. 31: P-ATM levels (Arbitrary Units) vs. age vs. the degree of insulin resistance. PC Positive 
control, Y Young, MA Middle aged. 
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c) P-ATM/T-ATM ratio 
No significant difference was seen in the P-ATM/T-ATM ratio of the human PBMCs when 
comparing age within each degree of insulin resistance (Figure 3.32).  
 
Figure 3. 32: P-ATM/T-ATM ratio (Arbitrary Units) vs. age vs. the degree of insulin resistance. 
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3. Western blotting for P22phox 
3.1 Control vs. od of 22 week old animal PBMCs 
No significant difference was seen between the P22phox levels of the od (n= 9) when compared to 
the age-matched controls (n= 7) (Figure 3.33). 
 
Figure 3. 33: P22phox levels (Arbitrary Units) of od vs. age-matched controls. PC Positive control. 
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3.2 Age comparison between animal PBMCs 
No significant differences were seen between the P22phox levels of the young control (n= 6) vs. 
control (n= 7) or the control vs. od (n= 9) (Figure 3.34). 
 
Figure 3. 34: P22phox levels (Arbitrary Units) of groups. PC Positive control. 
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3.3 Human PBMCs 
No significant differences were seen in the P22phox levels of the control (n= 8) vs. obese (n= 9) or 
the control vs. pre-diabetic (n= 7) (Figure 3.35). 
 
Figure 3. 35: P22phox levels (Arbitrary Units) vs the degree of insulin resistance. PC Positive control.  
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3.4 Degree of insulin resistance between human PBMCs vs. age 
No significant differences were seen in the P22phox levels of the Y obese or MA obese or Y pre-
diabetic or MA pre-diabetic when compared to the Y control or MA control or between Y and MA 
with in degree of insulin resistance (Figure 3.36).  
 
Figure 3. 36: P22phox levels (Arbitrary Units) vs. the degree of insulin resistance. PC Positive control, 
Y Young, MA Middle aged. 
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CHAPTER 4: DISCUSSION 
This chapter discusses the findings of an animal model measuring ATM levels in PBMCs as well as 
the findings when repeating these methods using human PBMCs previously harvested and 
collected from a biobank. Furthermore, the chapter discusses the possibility of ATM levels as a 
biomarker for insulin resistance. 
1. A summary of findings in the animal study 
The first aim of the study was to isolate PBMCs from rat blood and test whether the ATM protein 
was expressed in such levels that it can be measured by Western blotting. As shown in Chapter 2: 
Materials and Methods, a method was successfully developed and T-ATM was measured by 
Western blotting.  
As the main aim of the study was to test whether the ATM levels in PBMCs could reflect metabolic 
changes induced by obesity and insulin resistance, we utilised a rat model to test this before using 
PBMCs collected from patients. Previous animal studies done in this laboratory along with the 
current study have shown that this obesogenic diet (Table 2.3) caused increased body weight, IP 
fat mass and basal blood glucose levels and induces obesity and insulin resistance as determined 
by the OGTT (Reynés et al., 2016). An increase in IP fat mass, OGTT and basal blood glucose 
biometric measurements were seen when comparing the od data to that of the age-matched 
controls. A significant increase in body weight was seen between that of the young controls 
compared to controls. 
An overall increase was seen in the T- and P-ATM levels as well as the P-ATM/T-ATM ratio of the 
od animals when compared to the age-matched controls. This differs from related studies looking 
at adipocyte differentiation and glucose homeostasis in wild-type vs. knockout ATM mice showing 
decreased ATM expression in knockout mice (Takagi et al., 2015). Studies done in our laboratory 
also showed a decrease in ATM levels with a HFD. Studies in humans, specifically with AT, have 
shown results that suggested an age-associated decrease in DNA repair that could possibly be 
attributed to the decreased activity of ATM with age (as discussed in Chapter 1 Section 9.2, (Garm 
et al., 2013; Reynés et al., 2016)), and which may explain the decreased activity of ATM in the age-
matched controls compared to the young controls. Furthermore, the od model that we used may 
have caused oxidative stress or DNA damage that may have resulted in the higher T- and P-ATM 
levels. 
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1.1 Body weight and IP fat mass 
It is widely known that consuming diets that are high in fats, cholesterol, refined sugar and 
carbohydrates induce a state of over-nutrition (obesogenic) or malnourishment (unbalanced diet) 
and causes an imbalance in the homeostasis of the metabolism (Lee and Lee, 2014). The increase 
in body weight is aggravated by the increase in energy consumption, with increased food intake, 
but low activity levels (sedentary lifestyle) which may explain the significant difference seen 
between the body weights of the age-matched controls when compared to the young controls 
(Figure 3.1). As discussed in Chapter 1 Section 6.1.1, lipids are stored in adipose tissue and in an 
obese state the adipose tissue reaches maximum capacity, inducing lipolysis and subsequently an 
increase in circulating FFAs (Wang et al., 2017). Obese individuals have an increased fat deposition 
around the abdominal area, which was visible in the rats fed an od diet. 
There was no significant difference seen between the body weight of the od and age-matched 
control animals however, there was significance when comparing the IP fat mass (Figure 3.2), 
which supports the findings that obese individuals have an increased waist circumference. The 
significant difference seen between the body weight of the young controls and controls is possibly 
due to age, as older rats may be larger in size. 
1.2 OGTT and basal blood glucose levels 
The OGTT is performed to determine the animal’s ability to clear glucose from circulation, and is 
measured to determine glucose tolerance.  Following overnight fasting of the animals and 
gavaging with 1 g/kg sucrose, animals fed od showed a slower rate of clearance of blood glucose 
(mmol/L) from circulation compared to the controls (Figure 3.3). This indicated glucose intolerance 
in the od animals and animals were considered to be insulin resistant, but not diabetic. 
Glucose is one of the main sources of energy for the body that is manufactured during glycolysis, 
the metabolism of carbohydrates. Basal blood glucose levels are measured to determine whether 
there is normal glucose homeostasis and are measured following overnight fasting. According to 
the American Diabetes Association (2004a) normal fasting blood glucose is <5.6 mmol/L, impaired 
fasting glucose is between 5.6 – 6.9 mmol/L and diabetes is a fasting blood glucose of >7.0 
mmol/L. Levels were measured at time point 0 min and od animals were shown to have a 
significantly higher level of circulating blood glucose when compared to age-matched controls 
(Figure 3.4). Increased basal blood glucose levels in animals fed the od when compared to the age-
matched controls, suggest that the od-fed animals had a decreased glucose tolerance and insulin 
resistance. Hence, od animals’ cells were not as sensitive to circulating glucose and subsequent 
Stellenbosch University  https://scholar.sun.ac.za
 79 
 
insulin activity and therefore could not maintain glucose homeostasis when compared to the 
controls. This is also indicative of high basal circulating blood glucose which is similar to conditions 
seen in insulin resistant patients.  
1.3 Proteins in insulin signalling and obese conditions 
1.3.1 ATM 
As previously discussed, AT patients characteristically present with insulin resistance and have a 
higher prevalence of developing T2D. This suggested ATM plays a role in the insulin signalling 
pathway and glucose metabolism (Bar et al., 1978). The discovery of PKB activation in an ATM-
dependent manner due to insulin treatment or ionising radiation that initiates glucose uptake, was 
seen as proof of ATM’s role in metabolic pathways (reviewed in (Khalil, Tummala and Zhelev, 
2012)). Under obese conditions, and proven by the OGTT, the rats were shown to be insulin 
resistant. 
This study’s data is in agreement with literature, as Khalil et al. (2012) reviewed articles that 
reported insulin treatment or ionizing radiation activates ATM and subsequently the AMPK 
pathway or PBK pathway depending on the energy state of the cell and the level of ROS. Although 
not significant, the od animals showed, what appeared to be, a higher level of T- and P-ATM when 
compared to the controls (Figure 3.5 – Figure 3.7). From the review of Khalil et al. (2012), it is 
suggested that the possible increased levels of insulin could act as insulin treatment and 
subsequently increase ATM levels. However, under insulin resistant conditions, the cell has a 
decreased responsiveness to the stimulus of insulin and thus ATM is expected to be 
downregulated. The P-/T-ATM ratio is used to show how much of the total protein is active. No 
significance amongst the od vs. control ratios could suggest that although the od animals seemed 
to have an increased level of ATM, there were no significant differences between the groups.  
AT patients characteristically present with premature ageing (reviewed in (Shiloh and Lederman, 
2017)). Younger control animals were included to determine whether age would affect ATM levels. 
Studies investigating the parallel between rat age and human age found that rats reach 
reproductive maturity at 6 weeks and become socially mature at 5 – 6 months and that 1 month of 
rat age is equal to 2.5 – 3 human years (Andreollo et al., 2012; Sengupta, 2013). When 
comparisons were made with young controls, age had an effect on ATM activity, with significantly 
higher T-ATM levels of young controls compared to controls and significantly higher P-ATM levels 
of age-matched controls compared to young controls (Figure 3.8 and Figure 3.9). The P-ATM 
differed from a previous analysis of the same age-matched and od samples (Figure 3.6) and may 
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be due to a difference of a month between running the samples for the T-ATM and then for the P-
ATM.  Control animals had a significantly higher P-/T-ATM ratio compared to young controls, 
suggesting higher basal activity in the older animals, possibly due to more DSB in the older animals 
(Figure 3.10). However, the od animals had a significantly lower ratio (Figure 3.10) that may be 
due to the insulin resistance state lowering some of the intermediates responsible for ATM activity 
as reported by Halaby et al. (2008). 
1.3.2 P22phox 
The results obtained while probing for P22phox suggests no ROS or inflammation in the od animals. 
Although not significant, od P22phox levels appeared to be more than that of the age-matched 
controls (Figure 3.33). This could suggest that P22phox levels were elevated under insulin resistant 
conditions but not enough to be statistically significant. Significant differences might have 
occurred over a longer period of time once animals developed diabetes and with larger n-values. 
As obese conditions induce inflammation, P22phox is expected to be upregulated as inflammation 
causes the production of ROS which occurs via the NOXs.  
In conclusion, this animal study found that ATM levels can be measured in PBMCs and that the 
ATM levels are (i) susceptible to changes in insulin sensitivity, namely the normal state of insulin 
signalling seen in the controls and young controls and the insulin resistant state seen in the od 
animals as well as (ii) susceptible to the effects of age. Both these conditions caused fluctuations in 
the P- and T-ATM levels as well as ATM activity indicated by the ratio. 
2. A summary of findings in the human study 
Patients’ biometric data showed significant relationships between the degree of insulin resistance 
and the measurements taken. With the division into age groups, more significance was seen 
between the degree of insulin resistance and age within a measurement. Patients in the obese and 
pre-diabetic groups fitted into parameters commonly seen in obese with insulin resistance 
individuals, namely an increased BMI exceeding 30 kg/m2, increased waist circumference 
exceeding the 88 cm obesity parameter for females (Hough, 2004) subsequently increasing the 
WHR, increased TF/LF and fasting blood glucose. Of the whole lipid profile, significance was only 
seen in the triglyceride levels when comparing the Y pre-diabetic group to the Y control. 
No significance was seen in the T-ATM levels although the data seemed to have an increasing 
trend with an increase in the degree of insulin resistance. P-ATM levels showed significant 
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differences with an increase in the degree of insulin resistance as well as with the analysis with age 
groups. 
2.1 Obesity-related findings 
In South Africa NCDs are estimated to be responsible for 51% of deaths (WHO, 2018). The NCDs 
Country Profiles 2018 for South Africa reported that adult obesity at ages 18 and older were at 
15% for males and 39% for females and adolescent obesity between the ages of 10 – 19 years 
were at 9% for males and 13% for females in 2016. It is widely known that an unbalanced diet high 
in carbohydrates, sugar and fat would induce obesity and subsequently induce the development of 
other comorbidities and that a sedentary lifestyle would aggravate this disease. In 2016, the 
prevalence of adult (18 years and older) physical inactivity was 26% amongst males and 48% 
amongst females (WHO, 2018). The WHO (2018) reported that in 2014, 24% of both adult males 
and females had raised blood glucose levels. Epidemiological studies have shown a relationship 
between obesity and T2D, which was further investigated where healthy lean individuals, without 
any previous record of obesity or diabetes, were fed an over-nutritious diet and were found to 
develop insulin resistance (Sims and Danforth, 1987). 
BMI 
BMI was significantly higher in the obese and pre-diabetic groups when compared to the controls, 
thus suggesting an increase in body weight with an increase in insulin resistance. As previously 
mentioned (Chapter 1 Section 7.1.1b), in an obese state there is an increase in circulating FFAs, 
which aids the development of insulin resistance. With a constant state of high blood glucose, the 
state of insulin resistance further develops until the patient is pre-diabetic. This may explain the 
increase in BMI with an increase in insulin resistance.  Significant increases in BMI with the 
increase in insulin resistance was seen when differentiating between young and middle aged 
participants. Significance was also seen between the MA obese and pre-diabetics when compared 
to their respective controls. This may be explained by the probable decrease in physical activity 
that comes with age, which is also apparent when comparing the MA groups to the Y groups 
(Figure 3.11 and Figure 3.12). 
WHR 
The WHR is used to determine body fat distribution and a high ratio is normally indicative of 
abdominal adiposity, however, WHR can be influenced by other factors in the body and thus 
cannot be used in isolation (Sweeting, 2007). Adults with a high waist circumference have extra 
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morbidity along with diabetes and risk factors of cardiovascular disease (Lean, Han and Seidell, 
1998). This study’s findings are in agreement with literature. Participants’ WHR was seen to be 
significantly higher in the obese and pre-diabetic compared to control as well as in the Y obese and 
pre-diabetic groups compared to Y controls with an increase in the degree of insulin resistance 
(Figure 3.13 and Figure 3.14) suggesting a high level of visceral adiposity in the Y obese and Y pre-
diabetic groups. Four concepts are mentioned below that may explain the reason for the increased 
WHR with an increased degree of insulin resistance. 
BMI and WHR in insulin resistance 
A review article discussing the relationship between obesity and insulin resistance discussed 
recent concepts suggesting the possible reasons for the development of insulin resistance due to 
visceral adiposity (Hardy, Czecha and Corveraa, 2012). Four possible mechanisms through which 
visceral adiposity is linked to insulin resistance was discussed. Concept i) Visceral adipose tissue 
induces diabetes by secreting cytokines that induce the progression to insulin resistance in tissues 
like the liver and muscle; ii) visceral adipose accumulation is an indicator of the accumulation of 
ectopic lipids and lipotoxicity, causing insulin resistance of the liver and muscle; iii) excess 
accumulation of lipids in visceral adipose tissue induces diabetogenic properties such as the 
accumulation of macrophages in visceral adipose tissue which decreases insulin sensitivity and iv) 
peripheral tissue lipotoxicity and cytokine production in visceral adiposity contribute to insulin 
resistance (reviewed in (Hardy, Czecha and Corveraa, 2012)). 
TF/LF 
BMI and waist circumference are overall measures of obesity and central adiposity respectively 
(reviewed in (Wilson et al., 2013)). However, these measures do not provide information on the 
exact total fat mass. DXA is a medical imaging technique that can provide scan data on the whole 
body as well as fat mass, lean mass, bone mineral density and bone mineral content (Wilson et al., 
2013). A study was done to investigate trunk to leg volume ratio from DXA whole body scans and 
its relationship to diabetes and metabolic abnormalities. This study found that the prevalence of 
diabetes, elevated triglycerides, low HDL, increased blood pressure and metabolic syndrome with 
its associated mortality were linked to significantly increased trunk to leg volume ratio quartile 
(Wilson et al., 2013). Furthermore, amongst participants at a low risk with a normal BMI showed 
an increase of afore mentioned diseases with an increase in trunk to leg volume ratio. Although 
the current study used TF/LF instead of trunk to leg volume ratio the findings are in agreement 
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with literature, where an increase in TF/LF was seen with an increase in the degree of insulin 
resistance (Figure 3.15). If the TF/LF ratio is decreased, it indicates lower limb fat mass and more 
abdominal (trunk) fat mass. These findings showed a decrease in abdominal fat mass with age and 
an increase in abdominal fat mass with insulin resistance (Figure 3.16). Age and the degree of 
insulin resistance had an overall effect on TF/LF.  
Fasting blood glucose 
Fasting is considered as no calorie intake for at least 8 hours (American Diabetes Association, 
2004a). As previously mentioned, normal fasting glucose is <5.6 mmol/L, impaired fasting glucose 
is between 5.6 – 6.9 mmol/L and is also referred to as pre-diabetes and diabetes is >7.0 mmol/L 
(American Diabetes Association, 2004a). For this study, fasting blood glucose was measured after 
overnight fasting or at least 4 hours prior to blood glucose measurement via a finger prick. As 
expected, fasting blood glucose levels increased significantly with an increase in the degree of 
insulin resistance suggesting elevated levels of circulating glucose and suggesting insulin resistance 
as glucose is not effectively cleared from circulation (Figure 3.25). Y pre-diabetic participants 
fasting blood glucose levels were significantly higher than their control (Figure 3.26). In addition, a 
two-way ANOVA showed the positive relationship between increased blood glucose levels and 
insulin resistance. 
2.2 Lipid profile and obesity 
A lipid profile is created following a period of overnight fasting of at least 12 – 14 hours followed 
by the collection of blood samples and the determination of total cholesterol, LDL cholesterol, HDL 
cholesterol and triglyceride levels (Nigam, 2011). According to Nieves et al. (2003) the lipoprotein 
profile is influenced by obesity and insulin sensitivity and in conditions of increased intra-
abdominal fat and insulin resistance, patients have a more atherogenic lipid profile. An 
atherogenic profile has increased total cholesterol, LDL cholesterol and triglycerides and 
decreased HDL cholesterol (Nieves et al., 2003). A study by Nieves and colleagues (2003), looked 
at the atherogenic lipoprotein profile of obese and insulin resistant individuals and linked it to 
their intra-abdominal fat. Density gradient ultracentrifugation was performed to determine the 
lipoprotein content of most intra-abdominally obese and insulin resistant group and compared 
with the least intra-abdominally lean and insulin sensitive group and significant differences were 
seen across most of the fractions across the density gradient (Nieves et al., 2003). The study found 
that more abdominal obesity and decreased insulin sensitivity was associated with more 
cholesterol in the very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and 
Stellenbosch University  https://scholar.sun.ac.za
 84 
 
dense LDL fraction and less cholesterol in the HDL fractions. Furthermore, these findings were 
more strongly influenced by intra-abdominal fat than insulin sensitivity. Nieves and colleagues 
(2003) found that insulin sensitivity had no influence on cholesterol concentrations. 
In the current study, no significant relationship was seen between the total cholesterol, LDL 
cholesterol, HDL cholesterol or triglycerides levels of obese or pre-diabetic patients and their 
controls irrespective of the age parameter. Significance was only seen between the Y pre-diabetic 
and Y control groups’ triglyceride levels. From the data, the pre-diabetic group was shown to have 
the highest BMI, WHR and TF/LF compared to controls amongst the whole group once age was 
included. As previously discussed, obese individuals are unable to store surplus lipids which then 
circulate in the blood stream and may explain the elevated levels of triglycerides seen in the Y pre-
diabetics. HDL cholesterol levels tended to decrease with the degree of insulin resistance and this 
was also seen when the age parameter was included. Furthermore, there was a strong trend for 
an increase in triglyceride levels with the degree of insulin resistance. Unfortunately, the available 
n-values of samples were very small, especially when divided into different age parameters. The 
study will benefit from expanding these measurements in future. As discussed above, no 
significance was seen in the lipoprotein levels possibly due to the non-effect of insulin sensitivity 
on cholesterol levels as seen by Nieves et al. (2003). They suggest that, although insulin resistance 
is associated with a lipid profile seen in obese conditions, it seems as though this association is due 
to insulin resistance’s close relation to intra-abdominal fat.  
2.3 Blood pressure, Atherogenic Index and HTR 
According to Hardy et al. (2012), insulin resistance is considered a precursor for T2D and has been 
found to be associated with hypertension and dyslipidaemia. SBP and DBP were higher in the pre-
diabetic group when compared to the controls suggesting a hypertensive state (Table 3.2). With 
the separation into ages, SBP was elevated in MA pre-diabetics and this is possibly due to the 
hyperinsulinaemic state, which was statistically supported with a two-way ANOVA indicating age 
and the degree of insulin resistance had a significant overall effect on SBP (Table 3.3). MA obese 
and Y and MA pre-diabetic groups showed higher DBP compared to controls, indicating the effect 
of insulin resistance on blood pressure and, as was shown with a two-way ANOVA, the degree of 
insulin resistance had an overall significant effect on DBP (Table 3.3). Furthermore, pre-diabetics 
also had a lower HTR compared to controls (Table 3.2), suggesting that pre-diabetics had lower 
levels of HDL and higher levels of total cholesterol compared to controls. With age, no significant 
difference were seen in the HTR or Atherogenic index. HTR is dependent on HDL cholesterol and 
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total cholesterol which did not show significance when analysed in the group and when analysed 
with age (Figure 3.17, 3.18 and Figure 3.21, 3.22). These results may also be due to the small 
sample sizes per age group that was available in the biobank. The Atherogenic index is calculated 
based on total and HDL cholesterol and as previously discussed there were no significant 
differences seen in these parameters.  
2.4 Proteins in insulin signalling and obese conditions 
2.4.1 ATM  
The role of ATM in insulin signalling has been discussed in Section 1.3.1. Although not significant T-
ATM seemed to increase with an increase in the degree of insulin resistance (Figure 3.27). There 
was a significant increase in P-ATM with an increase in the degree of insulin resistance (Figure 
3.28). ATM can be activated by either oxidative stress or by metabolic signalling pathways or 
alternatively by DNA damage, resulting in elevated phosphorylation. In the insulin resistant state, 
especially in pre-diabetes, higher than normal insulin levels are expected which could have 
resulted in this increase in P-ATM. As no differences in P22phox was observed, there was no 
overproduction of ROS in these patients. Unfortunately, the insulin levels of the patients were not 
available, therefore it can only be speculated that this may have resulted in the higher levels of P-
ATM in the pre-diabetic vs. controls. 
For the Y and MA analysis the same data sets were used as for the degree of insulin resistance 
groups but split according to the age cut offs. Although not significant, the T-ATM levels seemed to 
increase with the degree of insulin resistance in both the Y and MA groups (Figure 3.30). The same 
was seen in the P-ATM data, however, significance was only seen between the Y pre-diabetic and 
Y control groups, this may be due to the low n – value  for the Y pre-diabetic (n= 3) compared to 
the high n – value  of the Y controls (n= 6) (Figure 3.31). The apparent implications of age on ATM 
expression and its use as a biomarker will be further discussed below. 
2.4.2 P22phox 
As previously discussed (Chapter 1 Section 6. P22phox), P22phox is used as an indicator of the level of 
ROS production as well as inflammation. P22phox was probed for to investigate whether cholesterol 
levels could be causing inflammation. No significant differences were seen in total, HDL or LDL 
cholesterol levels however, there was significance in the triglyceride results. Furthermore, no 
significance was seen in the P22phox data irrespective of the degree of insulin resistance or age.    
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3. ATM levels as a biomarker for insulin resistance 
The GWAS study by Zhou and colleagues (2011) reported variation in glycaemic response to 
metformin treatment. They concluded that ATM acts upstream of AMPK where it plays a role in 
the response to metformin and when there are variations in the ATM gene there are variations in 
the glycaemic response and the activation of AMPK by metformin. Patients on metformin were 
unfortunately excluded from the current study. 
Both triglyceride levels and blood glucose levels increased with the state of insulin resistance, 
coinciding with an increase in P-ATM but not in ATM expression levels, indicating that neither one 
influences the activity state of ATM. Age, on the other hand, seemed to affect the levels of ATM. 
4. Overall summary  
The od diet induced obesity and insulin resistance which was evident with the OGTT showing 
elevated basal blood glucose levels when compared to the controls (Figure 3.4) as well as a slower 
rate of glucose clearance from circulation which was not significant at any specific time point 
however, od had an overall effect on glucose clearance, suggesting decreased sensitivity to insulin 
(Figure 3.3). The od diet was intended to simulate a Westernised or malnourished/unbalanced diet 
and thus, induce the obese state which is similar to how humans develop metabolic related 
diseases. As expected, although not significant, the rats’ body weight seemed to be more than 
that of the controls, however, the expected significant difference was seen when comparing the IP 
fat mass suggesting abdominal adiposity as is often seen amongst obese individuals (Figure 3.1, 
Figure 3.2). 
The Western blotting results of the rat PBMCs, showed what appeared to be increased levels of T- 
and P-ATM, T/P ratio and P22phox. However, none of these findings were statistically significant. It 
is possible that with longer exposure to the od diet animals would have developed significant 
differences in the levels of these proteins. However, as it was shown by the OGTT data that these 
animals were insulin resistant, it could be suggested that insulin resistant conditions upregulated 
ATM as well as P22phox activity. Although a decrease in ATM levels were expected, the high 
circulating glucose levels may have induced an increase in circulating insulin and may have 
simulated insulin treatment which would have activated ATM intracellularly as discussed by Khalil 
et al. (2012). 
As previously mentioned and widely known, the current composition of what is known as a 
Westernised diet paired with a sedentary lifestyle has increased the prevalence of obesity 
Stellenbosch University  https://scholar.sun.ac.za
 87 
 
worldwide with a more apparent increase amongst children and adolescents (Chapter 1 Section 
7.1.1 Obesity), (Chapter 4 Section 2.1). A large portion of participants formed part of the obese 
group (data not shown) of which a few were selected for analysis. It could be speculated that 
these participants may later develop further insulin resistance and be reclassified at pre-diabetic 
or T2D. 
Speculative functioning of ATM under insulin resistant conditions 
Insulin resistant animals and humans showed increased levels of T- and P-ATM. As previously 
discussed, Viniegra and colleagues (2005) found that (i) ATM indirectly phosphorylates PKB at Ser-
473 following insulin treatment. It is possible that, although cells are supposed to be less sensitive 
to insulin, a possibly hyperinsulinaemic environment could act as insulin treatment causing an 
upregulation of ATM (Figure 4.1). According to Nishizawa and Bornfeldt (2012), (ii) insulin 
resistance conditions also cause inflammation due to high levels of circulating glucose which could 
subsequently cause the upregulation of the NOXs as well as P22phox which could explain the 
increase in P22phox, however, these findings were not significant. The opposite was seen in the 
human study. This may be explained by a possibly longer exposure to insulin resistant conditions 
than the animals, causing the (ii) inflammatory condition and (iii) increased ROS production and 
oxidative stress which would increase the phosphorylation of ATM. This may explain the significant 
increases of P-ATM (Figure 3.28). Furthermore, the (iv) upregulated P-ATM would then work to 
decrease ROS production which may explain the non-significant decrease in P22phox with the 
increase in insulin resistance. Additionally, although no data was collected for PKB and 4E-BP1, 
from the literature (Khalil, Tummala and Zhelev, 2012), it could be hypothesised that (v) the 
upregulation of ATM would subsequently upregulate GLUT4 translocation as well as protein 
synthesis (Figure 4.1).  
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Figure 4. 1: The functioning of ATM under insulin resistant conditions. Ataxia Telangiectasia 
Mutated (ATM), Protein kinase B (PKB), glucose transporter 4 (GLUT4), Serine (Ser), Eukaryotic 
translation initiation factor 4E – binding protein 1 (4E-BP1), Eukaryotic translation initiation factor 
4E (eIF-4E), NADPH oxidase 2 (NOX2), Reactive oxygen species (ROS), phosphorylated (P). 
5. Conclusion 
PBMCs are susceptible to changes in their micro- and macro-environments (Liew et al., 2005) as 
was shown by the changes in ATM and P22phox levels in an obese or insulin resistant environment. 
An unbalanced diet induced the development of obesity and insulin resistance in both animals and 
humans with both species showing an increase in basal/fasting blood glucose levels, abdominal fat 
distribution (IP fat mass, WHR, TF/LF) and overall body weight. The inconclusive lipid profile 
results suggest further investigation into the relationship between obesity, insulin resistance and 
cholesterol. The findings did indicate an increase in a hypertensive state with the degree of insulin 
resistance as well as age. This study established a working protocol for the isolation of PBMCs 
from rat whole blood and ATM levels were successfully measured in PBMCs. This protocol was 
successfully repeated with human samples.  
Due to the variation in ATM levels with the degree of insulin resistance and the compounding 
effect observed with age, it would be difficult to use ATM levels as a biomarker for insulin 
resistance. As previously discussed this variation may be due to gene variation affecting the 
glycaemic response.  
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CHAPTER 5: LIMITATIONS AND FUTURE RESEARCH 
 Rats fed the od developed obesity and insulin resistance, however there were no animal 
groups that simulated pre-diabetes and T2D. 
 The human study did not include a T2D group and the number of participants were very 
small. 
 This study only included participants of the black Xhosa female population. 
 The samples collected in the human study were shared amongst more than one project. 
Thus each sample used in this project contained very low protein concentrations and 
possibly may have affected the data outcomes. 
 The animal study made use of male rats and the human study made use of female 
participants.  
 Future animal studies: This study should be repeated with an animal study including a 
larger variation in the degree of insulin resistance and possibly a larger sample size per 
group. 
 Future human studies: The human study should be repeated with a larger sample size of at 
least 100 participants. The study should include both male and female groups for each 
degree of insulin resistance and a T2D group should be included. Blood samples should be 
collected solely for this project in order to obtain the highest possible protein 
concentration. The study should also be expanded to include other ethnic groups (e.g. 
Caucasian, Mixed Race). 
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